Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Request ID: to07_add_preg_ahr_wp003_nsdp_v02

Request Description: This report contains estimates of the prevalence of antidiabetic agent use among women 10 to 54 years of age who delivered a live-born infant between January 1, 2001 and December 31, 2013 in the Mini-Sentinel Distributed Database (MSDD). Results for antidiabetic agent use are also presented for a matched comparator cohort with no live-birth deliveries during the request period.

Sentinel Modular Program Tool Used: Pregnancy Tool Prototype, Modular Program 8

Data Source: Data from January 1, 2001 to December 31, 2013, from 15 Data Partners contributing to the MSDD were included in this report. This request was distributed to Data Partners on May 14, 2015. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: This request was designed to calculate descriptive statistics regarding characteristics of the pregnant population with live-birth deliveries and a matched non-pregnant comparator group, and to determine the frequency of pregnancy episodes and non-pregnant episodes exposed to antidiabetic agents of interest. Results were stratified by trimester, calendar year of delivery, and maternal age.

Sensitivity Analyses: Results were additionally presented within specific sub-cohorts of the pregnant and comparator groups. These sub-cohorts include members with a pre-existing condition (diabetes, lupus, or multiple sclerosis) and members with a previous dispensing of an antidiabetic agent.

Exposures of Interest: The exposures of interest used in this request were specific alpha-glucosidase inhibitors, amylin analogs, biguanides, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, meglitinide analogs, sulfonylureas, thiazolidinediones, combination products, and injectable insulin products. Please see Appendix B for a list of generic drug names used to define the exposures of interest in this request.

Pregnancy Episode Creation: A claims-based algorithm was used to identify pregnancies ending in a live birth.[1] This algorithm used International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes indicative of weeks of gestation, and ICD-9-CM diagnosis codes for pre-term and post-term deliveries, to calculate the length of the pregnancy episode. Codes had to occur within 7 days of a delivery date in the inpatient setting. In absence of pre-/post-term codes, pregnancy duration was set to 273 days. Pregnancies were excluded from the cohort if there was evidence of a prior delivery in the 301 days before the delivery date of interest. Please see Appendix C for a list of ICD-9-CM codes used in the gestational age algorithm, and Appendix D for codes to define live-birth delivery using Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and ICD-9-CM diagnosis and procedure codes.
Trimesters were defined by the following time periods during pregnancy:

1) First trimester: Day 1 to 90
2) Second trimester: Day 91 to 180
3) Third trimester: Day 181 to delivery date

Cohort Eligibility Criteria: Women included in the cohort were required to be continuously enrolled in plans with both medical and drug coverage for at least 480 days prior to the admission date of delivery, during which gaps in coverage of up to 45 days were allowed. The comparator group of non-pregnant women with similar eligibility criteria was identified, matching on age, enrollment criteria, and restriction criteria for pre-existing conditions or use of a medication in the period prior to pregnancy. Women aged 10 to 54 years were included in the cohorts.

Sub-cohort Criteria: The analytic sub-cohorts were defined as members with a pre-existing condition (diabetes, lupus, or multiple sclerosis) or prior dispensing of an antidiabetic agent. Women without any antidiabetic agent dispensing in the 183 days prior to the pregnancy episodes were further divided into those with and without a gestational diabetes diagnosis. Please see Appendices E and F for a list of diagnosis codes and gestational diabetes definitions used to define the sub-cohort inclusion criteria.

Limitations: Algorithms used to define exposures and covariates are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

---

[1] Andrade, S. E., et al. (2012). "Medication Exposure in Pregnancy Risk Evaluation Program." Matern Child Health J 16(7):1349-1354

Table of Contents

Age Stratifications - Age group categories for reporting. Specifying this parameter will (1) restrict to certain age groups and (2) specify how age groups will be stratified in the result tables. For example, to have results stratified by 20 year increments for members 40-99 years of age, AGESTRAT=40-59 60-79 80-99 would be entered.

Approval Date - Approval date of new molecular entity of interest.

Days of Supply Groups - Days of supply categories for reporting. This parameter will specify how claim days of supply will be stratified in result tables examining distribution of days supplied. For example, to have results stratified by 15 days increments for claims with 15-60 days of supply, DISPDAYSSUPSTRAT=15-29 30-44 45-60 would be entered.

Enrollment Days - Optional parameter to ensure a minimum number of days of continuous enrollment prior to the start of the first treatment episode.

Enrollment Gap - Sets the number of days that will be bridged between two consecutive enrollment periods to create a "continuously enrolled" period. For example, if ENROLGAP=30 and a member is eligible for medical and drug coverage in periods 1/1/2007-3/27/2007 and 4/1/2007-12/21/2007 (i.e., a 4-day gap between two consecutive enrollment episodes), the member will be considered continuously enrolled from 1/1/2007 to 12/21/2007. Any gaps in enrollment greater than 30 days will result in a new enrollment period, and all the days in the gap will be considered un-enrolled. A recommended enrollment gap is 45 days.

Episode Gap Type - Specifies the type of algorithm to use for the calculation of episode gaps. Valid values are: (1) F: Fixed episode gap. The value specified in EPISODEGAP will be used to determine if two consecutive claims are in the same episode; and (2) P: Percentage episode gap. The value specified in EPISODEGAP will represent a percentage of the previous dispensing's days of supply to determine if two consecutive claims are in the same episode.

Episode Gap - For a given claim, if EPISODEGAPTYPE is Fixed (F), a gap of more than EPISODEGAP days between the claim date and the date of the last day of supply of the previous claim triggers a new treatment episode. If EPISODEGAPTYPE is Percentage (P), a gap of more than EPISODEGAP percent of the previous claim days of supply days between the claim date and the date of the last day of supply of the previous claim triggers a new treatment episode.

Exposure - NDC and/or procedure and/or diagnosis code values for the exposure(s) of interest.

Exposure Extension Period - Extends the length of the treatment episode by a specified number of days. A treatment episode can be extended EXPEXTPER days after the last day of supply of the treatment episode's last claim.

New Molecular Entity (NME) Indicator - Specifies whether exposures should be treated as a NME; that is, the MP algorithm will not look prior to the query period start date (either approval or launch date) when applying the washout (WASHPER) condition. This parameter has no impact on how ENRDAYS is processed, i.e., when ENRDAYS is specified the program will always look for enrollment prior to the query period start date if necessary.

Maximum Days Supplied - Maximum days of supply for a claim to be valid.

Minimum Days Supplied - Minimum days of supply for a dispensing to be valid.

Minimum Episode Duration - Used to reject members with first treatment episode of fewer than a certain number of days.

Stockpiling Type - Specifies the type of stockpiling algorithm to use. Valid values are: (1) S: Standard algorithm. Slides overlapping dispensings to create a continuous sequence of non-overlapping dispensings; and (2) R: Revised algorithm. If a second dispensing occurs at least XX% (i.e., XX% or more) of the time through the previous dispensing, the length of the second dispensing is added to the end of the first dispensing; if the second dispensing occurs less than XX% of the time through the first dispensing then the second dispensing time is begun at the time it is dispensed and the first one is truncated.

Stockpiling Percent - Used in conjunction with Stockpiling Type to specify the percentage to be applied when Stockpiling Type = R

Study End Date - Query period end date.

Total Days of Supply Thresholds - Total days of supply threshold(s) for reporting. This parameter will specify how members' total days of supply (for all observed dispensings) will be stratified in the result tables examining distribution of members by number of total days supplied. For example, to have results stratified by 60 total days of supply, TOTALDAYSSUPTHRESH=060 120 180 240 300 would be entered.

Washout Period - Length of washout period in days. The washout period is a period of time before an incident exposure index date during which a member cannot have any evidence of exposure(s) of interest.

*all terms may not be used in this report

Table 1. Characteristics of the Pregnant Cohort and Non-Pregnant Cohort[1,2] Stratified by Presence of Pre-Existing Conditions of Diabetes, Lupus, or Multiple Sclerosis (MS) in the Mini-Sentinel Distributed Database (MSDD)

Characteristic	Episodes Among All Members	Episodes Among Members with Diabetes	Episodes Among Members with Lupus	Episodes Among Members with MS
Pregnant Cohort				
Total unique women with a pregnancy episode	1,598,705	14,216	2,183	2,048
Total unique women with pregnancy episode with antidiabetic agent	76,588	13,138	123	109
Total unique women with pregnancy episode without antidiabetic agent	1,531,584	1,116	2,064	1,946
Total unique pregnancy episodes	1,895,604	15,606	2,323	2,197
Total unique pregnancy episodes with antidiabetic agent	82,676	14,488	126	109
Total unique pregnancy episodes without antidiabetic agent	1,812,928	1,118	2,197	2,088
Calendar year of delivery admission				
2001	41,870	245	25	21
2002	62,345	462	54	33
2003	62,310	492	41	37
2004	61,544	585	52	40
2005	64,573	581	69	62
2006	68,056	626	59	54
2007	122,674	1,040	136	159
2008	146,443	1,271	171	171
2009	246,203	1,946	324	298
2010	275,835	2,330	359	358
2011	263,694	2,132	375	325
2012	252,272	2,107	331	313
2013	227,785	1,789	327	326
Maternal age at delivery, years				
< 20	115,584	404	49	17
20-24	260,013	1,608	227	117
25-29	495,250	3,545	544	453
30-34	610,703	4,949	845	891
35-39	329,080	3,745	512	567
40-44	76,995	1,082	127	132
45-54	7,979	273	19	20

Table 1. Characteristics of the Pregnant Cohort and Non-Pregnant Cohort[1,2] Stratified by Presence of Pre-Existing Conditions of Diabetes, Lupus, or Multiple Sclerosis (MS) in the Mini-Sentinel Distributed Database (MSDD)

Characteristic	Episodes Among All Members	Episodes Among Members with Diabetes	Episodes Among Members with Lupus	Episodes Among Members with MS
Specific codes for preterm birth				
644.21	134,681	2,776	337	197
765.0*	1,843	30	3	3
765.1*	29,480	707	76	39
765.2	1,060	19	6	1
765.21	741	14	1	2
765.22	287	4	3	0
765.23	558	11	4	1
765.24	645	12	2	0
765.25	1,020	25	5	3
765.26	2,061	55	3	4
765.27	5,377	147	16	8
765.28	14,898	359	38	19
Any code for preterm birth	146,523	3,108	373	218
Specific codes for postterm birth				
645.1*	254,786	283	137	235
645.2*	4,694	21	1	8
766.21	7,242	15	3	6
766.22	119	0	0	0
Any code for postterm birth	259,572	309	139	241
Medications used in the pre-pregnancy period				
Antidiabetic medications	15,606	15,606	34	24
Pre-Existing conditions				
Lupus	2,323	34	2,323	18
Multiple Sclerosis	2,197	24	18	2,197

Table 1. Characteristics of the Pregnant Cohort and Non-Pregnant Cohort[1,2] Stratified by Presence of Pre-Existing Conditions of Diabetes, Lupus, or Multiple Sclerosis (MS) in the Mini-Sentinel Distributed Database (MSDD)

Characteristic	Episodes Among All Members	Episodes Among Members with Diabetes	Episodes Among Members with Lupus	Episodes Among Members with MS
Non-Pregnant Cohort[1,2]				
Total unique women with a non-pregnant episode	1,582,856	14,036	2,116	2,007
Total unique women with a non-pregnant episode with antidiabetic agent	37,379	12,939	67	58
Total unique women with a non-pregnant episode without antidiabetic agent	1,547,500	1,135	2,049	1,949
Total unique non-pregnant episodes	1,895,604	15,597	2,284	2,169
Total unique non-pregnant episodes with antidiabetic agent	42,614	14,406	71	64
Total unique non-pregnant episodes without antidiabetic agent	1,852,990	1,191	2,213	2,105
Calendar year of matched comparator's delivery				
2001	41,870	244	24	21
2002	62,345	461	50	32
2003	62,310	492	37	35
2004	61,544	584	50	39
2005	64,573	580	66	59
2006	68,056	625	56	53
2007	122,674	1,038	133	156
2008	146,443	1,271	165	169
2009	246,203	1,946	317	295
2010	275,835	2,329	359	355
2011	263,694	2,131	373	323
2012	252,272	2,107	329	309
2013	227,785	1,789	325	323
Age at matched comparator's delivery				
< 20	115,584	404	43	15
20-24	259,895	1,606	221	105
25-29	495,231	3,538	532	444
30-34	610,770	4,947	836	887
35-39	329,150	3,747	507	566
40-44	76,981	1,082	126	132
45-54	7,993	273	19	20

Table 1. Characteristics of the Pregnant Cohort and Non-Pregnant Cohort[1,2] Stratified by Presence of Pre-Existing Conditions of Diabetes, Lupus, or Multiple Sclerosis (MS) in the Mini-Sentinel Distributed Database (MSDD)

Characteristic	Episodes Among All Members	Episodes Among Members with Diabetes	Episodes Among Members with Lupus	Episodes Among Members with MS
Medications used in the pre-nonpregnant period				
Antidiabetic medications	0	15,597	0	0
Pre-Existing conditions				
Lupus	0	0	2,284	0
Multiple Sclerosis	0	0	0	2,169

[1]Calendar year of delivery for the non-pregnant cohort is defined as the year of each woman's matched pregnant comparator's live-birth delivery date.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 2a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Pregnant Cohort						
Available unique episodes	1,895,604	1,895,604	1,895,604	1,895,604	1,895,122	1,895,122
Any Antidiabetic Agent	38,017	82,676	40,013	35,587	63,483	20,116
Specific Antidiabetic Agents						
Alpha-Glucosidase Inhibitors (Any Agent)	21	149	19	24	129	1
Alpha-Glucosidase Inhibitors (Specific Agent)						
Acarbose	17	145	17	22	127	1
Miglitol	4	4	2	2	2	0
Amylin Analog (Any Agent)	55	48	46	9	5	2
Amylin Analog (Specific Agent)						
Pramlintide	55	48	46	9	5	2
Biguanide (Any Agent)	30,194	32,757	29,431	15,827	9,897	6,535
Biguanide (Specific Agent)						
Metformin	30,194	32,757	29,431	15,827	9,897	6,535
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	226	242	227	87	50	35
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)						
Alogliptin	0	0	0	0	0	0
Linagliptin	5	6	4	2	2	0
Saxagliptin	26	30	30	10	3	3
Sitagliptin	195	206	193	75	45	32
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	403	333	316	77	32	22
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)						
Exenatide	298	238	224	55	25	17
Liraglutide	108	96	93	22	7	5
Meglitinide Analogs (Any Agent)	45	44	43	12	2	1
Meglitinide Analogs (Specific Agent)						
Nateglinide	30	26	26	8	1	1
Repaglinide	15	18	17	4	1	0

Table 2a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Sulfonylureas (Any Agent)	2,018	28,240	2,748	6,325	26,234	1,074
Sulfonylureas (Specific Agent)						
Acetohexamide	0	0	0	0	0	0
Chlorpropamide	0	5	3	1	3	1
Glimepiride	312	280	255	97	61	35
Glipizide	675	768	617	316	218	78
Glyburide	976	27,269	1,868	5,905	25,973	912
Tolazamide	80	82	82	53	23	23
Tolbutamide	5	3	3	2	1	1
Thiazolidinediones (Any Agent)	965	874	841	274	123	90
Thiazolidinediones (Specific Agent)						
Pioglitazone	712	660	635	223	102	77
Rosiglitazone	271	232	224	52	21	13
Combination Products (Any Agent)	565	633	520	204	155	59
Combination Products (Specific Agent)						
Alogliptin combination products	0	0	0	0	0	0
Glipizide combination products	24	22	20	5	2	1
Glyburide combination products	156	238	146	82	105	26
Linagliptin combination products	2	3	3	1	0	0
Pioglitazone combination products	138	125	121	35	10	9
Repaglinide combination products	1	0	0	0	0	0
Rosiglitazone combination products	109	95	89	24	9	2
Saxagliptin combination products	21	22	20	9	4	3
Sitagliptin combination products	130	141	131	50	26	17
Injectable Insulin Product (Any Agent)	7,351	34,476	12,289	18,028	33,447	11,461
Injectable Insulin Product (Specific Agent)						
Rapid-acting	5,842	25,959	10,074	14,602	24,705	9,064
Intermediate-acting	1,803	26,103	6,607	11,824	24,745	5,633
Long-acting	2,394	4,834	2,846	2,791	3,436	1,514
Other-acting	598	1,556	854	794	976	323

Table 2a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Non-Pregnant Cohort[1,2]						
Available unique episodes	1,895,604	1,895,604	1,895,604	1,895,604	1,895,122	1,895,122
Any Antidiabetic Agent	31,020	42,614	32,418	33,360	34,525	24,380
Specific Antidiabetic Agents						
Alpha-Glucosidase Inhibitors (Any Agent)	65	113	58	61	70	21
Alpha-Glucosidase Inhibitors (Specific Agent)						
Acarbose	44	80	37	39	51	13
Miglitol	21	33	21	22	19	8
Amylin Analog (Any Agent)	97	188	113	123	115	52
Amylin Analog (Specific Agent)						
Pramlintide	97	188	113	123	115	52
Biguanide (Any Agent)	19,994	30,518	21,207	21,933	22,886	13,845
Biguanide (Specific Agent)						
Metformin	19,994	30,518	21,207	21,933	22,886	13,845
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	417	773	478	502	576	296
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)						
Alogliptin	0	0	0	0	0	0
Linagliptin	14	43	23	29	35	16
Saxagliptin	53	114	66	73	89	40
Sitagliptin	351	621	389	400	454	238
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	844	1,344	878	927	950	513
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)						
Exenatide	576	866	585	588	568	312
Liraglutide	274	511	302	345	390	193
Meglitinide Analogs (Any Agent)	115	156	108	107	113	67
Meglitinide Analogs (Specific Agent)						
Nateglinide	69	89	58	60	63	36
Repaglinide	47	68	50	47	50	31

Table 2a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Sulfonylureas (Any Agent)	3,907	5,683	4,171	4,257	4,465	2,938
Sulfonylureas (Specific Agent)						
Acetohexamide	0	0	0	0	0	0
Chlorpropamide	4	5	2	3	4	1
Glimepiride	719	1,128	765	802	862	500
Glipizide	1,620	2,422	1,776	1,801	1,911	1,251
Glyburide	1,423	2,036	1,484	1,477	1,523	987
Tolazamide	187	268	209	226	225	164
Tolbutamide	5	5	5	5	4	4
Thiazolidinediones (Any Agent)	1,562	2,232	1,594	1,602	1,651	1,051
Thiazolidinediones (Specific Agent)						
Pioglitazone	1,187	1,748	1,240	1,266	1,293	826
Rosiglitazone	395	551	379	360	378	210
Combination Products (Any Agent)	1,158	1,706	1,211	1,232	1,265	799
Combination Products (Specific Agent)						
Alogliptin combination products	0	0	0	0	0	0
Glipizide combination products	51	60	49	46	41	30
Glyburide combination products	310	441	317	334	327	216
Linagliptin combination products	2	7	4	6	6	3
Pioglitazone combination products	232	341	229	230	241	143
Repaglinide combination products	0	2	1	2	1	1
Rosiglitazone combination products	187	272	196	178	171	102
Saxagliptin combination products	33	91	48	59	71	31
Sitagliptin combination products	363	549	390	398	426	267

Table 2a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Injectable Insulin Product (Any Agent)	9,815	11,663	10,048	10,217	10,381	8,689
Injectable Insulin Product (Specific Agent)						
Rapid-acting	7,599	9,167	7,710	7,849	7,907	6,362
Intermediate-acting	1,710	2,241	1,698	1,713	1,649	1,152
Long-acting	4,216	5,758	4,385	4,475	4,640	3,249
Other-acting	1,019	1,370	1,031	1,014	1,049	717

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 2b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Pregnant Cohort with Diabetes						
Available unique episodes	15,606	15,606	15,606	15,606	15,594	15,594
Any Antidiabetic Agent	13,847	14,488	13,322	12,876	12,998	11,553
Specific Antidiabetic Agents						
Alpha-Glucosidase Inhibitors (Any Agent)	21	28	16	12	12	1
Alpha-Glucosidase Inhibitors (Specific Agent)						
Acarbose	17	25	14	10	11	1
Miglitol	4	3	2	2	1	0
Amylin Analog (Any Agent)	55	44	42	8	5	2
Amylin Analog (Specific Agent)						
Pramlintide	55	44	42	8	5	2
Biguanide (Any Agent)	6,024	5,886	5,572	3,533	2,257	1,904
Biguanide (Specific Agent)						
Metformin	6,024	5,886	5,572	3,533	2,257	1,904
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	226	223	214	80	41	32
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)						
Alogliptin	0	0	0	0	0	0
Linagliptin	5	6	4	2	2	0
Saxagliptin	26	27	27	9	3	3
Sitagliptin	195	190	183	69	36	29
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	403	316	304	70	30	22
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)						
Exenatide	298	226	217	49	23	17
Liraglutide	108	91	88	21	7	5
Meglitinide Analogs (Any Agent)	45	43	42	12	2	1
Meglitinide Analogs (Specific Agent)						
Nateglinide	30	25	25	8	1	1
Repaglinide	15	18	17	4	1	0

Table 2b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Sulfonylureas (Any Agent)	2,018	2,803	1,916	1,532	1,414	564
Sulfonylureas (Specific Agent)						
Acetohexamide	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0
Glimepiride	312	251	240	88	46	32
Glipizide	675	596	573	270	91	74
Glyburide	976	2,001	1,097	1,162	1,268	411
Tolazamide	80	74	74	47	22	22
Tolbutamide	5	3	3	2	1	1
Thiazolidinediones (Any Agent)	965	800	786	258	104	88
Thiazolidinediones (Specific Agent)						
Pioglitazone	712	609	596	211	90	76
Rosiglitazone	271	208	207	48	14	12
Combination Products (Any Agent)	565	502	480	166	73	55
Combination Products (Specific Agent)						
Alogliptin combination products	0	0	0	0	0	0
Glipizide combination products	24	20	20	4	1	1
Glyburide combination products	156	148	132	62	35	24
Linagliptin combination products	2	2	2	0	0	0
Pioglitazone combination products	138	107	106	27	8	8
Repaglinide combination products	0	0	0	0	0	0
Rosiglitazone combination products	109	86	84	21	5	2
Saxagliptin combination products	21	22	20	9	4	3
Sitagliptin combination products	130	129	125	45	21	16
Injectable Insulin Product (Any Agent)	7,351	11,796	9,625	10,776	11,328	9,070
Injectable Insulin Product (Specific Agent)						
Rapid-acting	5,842	10,972	8,278	9,714	10,312	7,564
Intermediate-acting	1,803	6,850	4,398	5,705	6,123	3,737
Long-acting	2,394	3,191	2,588	2,196	1,923	1,343
Other-acting	598	927	756	603	409	267

Table 2b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Non-Pregnant Cohort[1,2] with Diabetes						
Available unique episodes	15,597	15,597	15,597	15,597	15,585	15,585
Any Antidiabetic Agent	14,374	14,406	13,579	13,033	12,705	11,605
Specific Antidiabetic Agents						
Alpha-Glucosidase Inhibitors (Any Agent)	30	50	28	35	39	17
Alpha-Glucosidase Inhibitors (Specific Agent)						
Acarbose	23	33	20	22	26	13
Miglitol	7	17	8	13	13	4
Amylin Analog (Any Agent)	95	150	103	99	89	45
Amylin Analog (Specific Agent)						
Pramlintide	95	150	103	99	89	45
Biguanide (Any Agent)	6,212	6,762	5,833	5,448	5,273	4,235
Biguanide (Specific Agent)						
Metformin	6,212	6,762	5,833	5,448	5,273	4,235
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	352	481	368	354	342	233
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)						
Alogliptin	0	0	0	0	0	0
Linagliptin	12	22	12	13	15	6
Saxagliptin	41	69	43	46	51	26
Sitagliptin	302	401	315	298	278	195
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	606	762	562	531	532	333
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)						
Exenatide	424	515	380	343	331	206
Liraglutide	183	271	190	197	204	120
Meglitinide Analogs (Any Agent)	74	99	70	65	65	40
Meglitinide Analogs (Specific Agent)						
Nateglinide	46	63	41	40	41	23
Repaglinide	28	37	30	26	24	17

Table 2b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Sulfonylureas (Any Agent)	2,773	3,161	2,670	2,565	2,460	1,941
Sulfonylureas (Specific Agent)						
Acetohexamide	0	0	0	0	0	0
Chlorpropamide	3	2	2	1	1	1
Glimepiride	497	615	484	490	461	335
Glipizide	1,183	1,431	1,180	1,140	1,109	842
Glyburide	979	1,044	885	833	796	628
Tolazamide	141	154	146	137	124	113
Tolbutamide	3	3	3	2	2	2
Thiazolidinediones (Any Agent)	1,140	1,357	1,077	1,044	952	
Thiazolidinediones (Specific Agent)						
Pioglitazone	849	1,041	817	804	731	515
Rosiglitazone	314	351	276	252	233	162
Combination Products (Any Agent)	821	956	774	733	707	519
Combination Products (Specific Agent)						
Alogliptin combination products	0	0	0	0	0	0
Glipizide combination products	26	36	25	23	23	12
Glyburide combination products	221	245	201	192	182	138
Linagliptin combination products	1	7	3	4	7	3
Pioglitazone combination products	174	194	160	139	140	102
Repaglinide combination products	0	0	0	0	0	0
Rosiglitazone combination products	139	160	125	121	102	72
Saxagliptin combination products	41	61	42	47	51	32
Sitagliptin combination products	229	298	233	219	221	152

Table 2b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Injectable Insulin Product (Any Agent)	7,197	7,779	7,074	7,045	7,039	6,226
Injectable Insulin Product (Specific Agent)						
Rapid-acting	5,584	6,236	5,496	5,531	5,456	4,640
Intermediate-acting	1,208	1,442	1,148	1,106	1,091	801
Long-acting	3,110	3,872	3,067	3,095	3,112	2,297
Other-acting	701	839	650	642	622	437

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 2c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Pregnant Cohort with Lupus						
Available unique episodes	2,323	2,323	2,323	2,323	2,322	2,322
Any Antidiabetic Agent	51	126	56	61	99	29
Specific Antidiabetic Agents						
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)						
Acarbose	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0
Amylin Analog (Specific Agent)						
Pramlintide	0	0	0	0	0	0
Biguanide (Any Agent)	33	39	34	19	13	8
Biguanide (Specific Agent)						
Metformin	33	39	34	19	13	8
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)						
Alogliptin	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0
Sitagliptin	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	1	1	1	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)						
Exenatide	1	1	1	0	0	0
Liraglutide	0	0	0	0	0	0
Meglitinide Analogs (Any Agent)	1	1	1	0	0	0
Meglitinide Analogs (Specific Agent)						
Nateglinide	0	0	0	0	0	0
Repaglinide	1	1	1	0	0	0

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Sulfonylureas (Any Agent)	3	40	2	10	37	0
Sulfonylureas (Specific Agent)						
Acetohexamide	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0
Glimepiride	1	1	0	1	1	0
Glipizide	1	1	1	0	0	0
Glyburide	1	38	1	9	36	0
Tolazamide	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	3	3	2	2	1	1
Thiazolidinediones (Specific Agent)						
Pioglitazone	3	3	2	2	1	1
Rosiglitazone	0	0	0	0	0	0
Combination Products (Any Agent)	0	0	0	0	0	0
Combination Products (Specific Agent)						
Alogliptin combination products	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0
Glyburide combination products	0	0	0	0	0	0
Linagliptin combination products	0	0	0	0	0	0
Pioglitazone combination products	0	0	0	0	0	0
Repaglinide combination products	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0
Sitagliptin combination products	0	0	0	0	0	0
Injectable Insulin Product (Any Agent)	15	61	21	35	57	18
Injectable Insulin Product (Specific Agent)						
Rapid-acting	11	46	16	28	44	14
Intermediate-acting	2	43	9	22	41	8
Long-acting	5	7	5	3	5	3
Other-acting	3	2	2	2	1	1

Table 2c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Non-Pregnant Cohort[1,2] with Lupus						
Available unique episodes	2,284	2,284	2,284	2,284	2,283	2,283
Any Antidiabetic Agent	66	71	59	53	60	44
Specific Antidiabetic Agents						
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)						
Acarbose	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0
Amylin Analog (Specific Agent)						
Pramlintide	0	0	0	0	0	0
Biguanide (Any Agent)	38	49	37	33	36	23
Biguanide (Specific Agent)						
Metformin	38	49	37	33	36	23
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	1	2	1	1	1	0
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)						
Alogliptin	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0
Sitagliptin	1	2	1	1	1	0
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	1	4	2	3	3	2
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)						
Exenatide	0	1	1	1	1	1
Liraglutide	1	3	1	2	2	1
Meglitinide Analogs (Any Agent)	2	3	3	2	2	2
Meglitinide Analogs (Specific Agent)						
Nateglinide	2	3	3	2	2	2
Repaglinide	0	0	0	0	0	0

Table 2c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Sulfonylureas (Any Agent)	10	10	8	9	9	8
Sulfonylureas (Specific Agent)						
Acetohexamide	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0
Glimepiride	2	3	1	2	2	1
Glipizide	4	4	4	4	4	4
Glyburide	4	3	3	3	3	3
Tolazamide	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	6	4	3	1	3	1
Thiazolidinediones (Specific Agent)						
Pioglitazone	5	3	2	0	2	0
Rosiglitazone	1	1	1	1	1	1
Combination Products (Any Agent)	2	3	2	3	3	2
Combination Products (Specific Agent)						
Alogliptin combination products	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0
Glyburide combination products	2	2	2	2	2	2
Linagliptin combination products	0	0	0	0	0	0
Pioglitazone combination products	0	2	1	2	1	0
Repaglinide combination products	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0
Sitagliptin combination products	1	1	1	1	1	1

Table 2c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Injectable Insulin Product (Any Agent)	25	24	20	20	22	18
Injectable Insulin Product (Specific Agent)						
Rapid-acting	17	18	13	12	14	10
Intermediate-acting	2	3	2	1	1	0
Long-acting	9	16	10	11	15	9
Other-acting	5	5	3	4	4	2

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 2d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Pregnant Cohort with MS						
Available unique episodes	2,197	2,197	2,197	2,197	2,196	2,196
Any Antidiabetic Agent						
Specific Antidiabetic Agents	53	109	53	42	84	26
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)						
Acarbose	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0
Amylin Analog (Specific Agent)						
Pramlintide	0	0	0	0	0	0
Biguanide (Any Agent)	41	41	38	16	11	7
Biguanide (Specific Agent)						
Metformin	41	41	38	16	11	7
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	1	1	1	1	0	0
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)						
Alogliptin	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0
Sitagliptin	1	1	1	1	0	0
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)						
Exenatide	0	0	0	0	0	0
Liraglutide	0	0	0	0	0	0
Meglitinide Analogs (Any Agent)	1	1	1	1	0	0
Meglitinide Analogs (Specific Agent)						
Nateglinide	1	1	1	1	0	0
Repaglinide	0	0	0	0	0	0

Table 2d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Sulfonylureas (Any Agent)	1	42	5	11	40	3
Sulfonylureas (Specific Agent)						
Acetohexamide	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0
Glimepiride	0	0	0	0	0	0
Glipizide	1	1	1	1	0	0
Glyburide	0	41	4	10	40	3
Tolazamide	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	2	2	2	2	2	2
Thiazolidinediones (Specific Agent)						
Pioglitazone	1	1	1	1	1	1
Rosiglitazone	1	1	1	1	1	1
Combination Products (Any Agent)	1	1	1	1	0	0
Combination Products (Specific Agent)						
Alogliptin combination products	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0
Glyburide combination products	0	0	0	0	0	0
Linagliptin combination products	0	0	0	0	0	0
Pioglitazone combination products	0	0	0	0	0	0
Repaglinide combination products	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0
Sitagliptin combination products	1	1	1	1	0	0
Injectable Insulin Product (Any Agent)	13	38	14	17	38	13
Injectable Insulin Product (Specific Agent)						
Rapid-acting	10	30	13	15	30	13
Intermediate-acting	2	29	6	9	28	5
Long-acting	5	6	5	2	4	2
Other-acting	1	4	1	2	4	1

Table 2d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Non-Pregnant Cohort[1,2] with MS						
Available unique episodes	2,169	2,169	2,169	2,169	2,168	2,168
Any Antidiabetic Agent	55	64	54	54	57	45
Specific Antidiabetic Agents						
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)						
Acarbose	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0
Amylin Analog (Any Agent)	2	2	2	1	2	1
Amylin Analog (Specific Agent)						
Pramlintide	2	2	2	1	2	1
Biguanide (Any Agent)	33	38	30	29	30	22
Biguanide (Specific Agent)						
Metformin	33	38	30	29	30	22
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)						
Alogliptin	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0
Sitagliptin	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	6	6	5	5	5	3
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)						
Exenatide	3	3	2	2	3	1
Liraglutide	3	3	3	3	2	2
Meglitinide Analogs (Any Agent)	0	0	0	0	0	0
Meglitinide Analogs (Specific Agent)						
Nateglinide	0	0	0	0	0	0
Repaglinide	0	0	0	0	0	0

Table 2d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Sulfonylureas (Any Agent)	2	3	3	3	1	1
Sulfonylureas (Specific Agent)						
Acetohexamide	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0
Glimepiride	0	1	1	1	1	1
Glipizide	1	1	1	1	0	0
Glyburide	1	1	1	1	0	0
Tolazamide	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	2	3	3	1	1	1
Thiazolidinediones (Specific Agent)						
Pioglitazone	2	2	2	1	1	1
Rosiglitazone	0	1	1	0	0	0
Combination Products (Any Agent)	0	1	1	1	1	1
Combination Products (Specific Agent)						
Alogliptin combination products	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0
Glyburide combination products	0	1	1	1	1	1
Linagliptin combination products	0	0	0	0	0	0
Pioglitazone combination products	0	0	0	0	0	0
Repaglinide combination products	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0
Sitagliptin combination products	0	0	0	0	0	0

Table 2d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Injectable Insulin Product (Any Agent)	22	24	23	22	22	20
Injectable Insulin Product (Specific Agent)						
Rapid-acting	19	23	21	21	19	17
Intermediate-acting	3	3	2	2	1	0
Long-acting	8	8	8	8	6	6
Other-acting	3	3	3		3	3

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Pregnant Cohort													
Available unique episodes	41,870	62,345	62,310	61,544	64,573	68,056	122,674	146,443	246,203	275,835	263,694	252,272	227,785
Any Antidiabetic Agent	950	1,607	1,828	2,073	2,200	2,393	4,912	6,030	11,338	12,926	12,324	12,222	11,873
Specific Antidiabetic Agents													
Alpha-Glucosidase Inhibitors (Any Agent)	2	1	0	0	0	2	9	25	20	23	21	22	24
Alpha-Glucosidase Inhibitors (Specific Agent)													
Acarbose	2	1	0	0	0	1	8	24	19	23	21	22	24
Miglitol	0	0	0	0	0	1	1	1	1	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0	4	6	10	11	5	6	6
Amylin Analog (Specific Agent)													
Pramlintide	0	0	0	0	0	0	4	6	10	11	5	6	6
Biguanide (Any Agent)	136	326	445	595	685	769	1,998	2,592	4,725	5,417	5,233	5,135	4,701
Biguanide (Specific Agent)													
Metformin	136	326	445	595	685	769	1,998	2,592	4,725	5,417	5,233	5,135	4,701
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	0	7	20	38	41	39	41	56
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)													
Alogliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0	0	0	0	0	2	4
Saxagliptin	0	0	0	0	0	0	0	0	0	1	7	7	15
Sitagliptin	0	0	0	0	0	0	7	20	38	40	32	32	37
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	0	0	2	24	37	63	43	44	53	67
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)													
Exenatide	0	0	0	0	0	2	24	37	63	41	22	23	26
Liraglutide	0	0	0	0	0	0	0	0	0	2	22	30	42
Meglitinide Analogs (Any Agent)	0	2	3	4	3	3	2	0	5	8	6	4	4
Meglitinide Analogs (Specific Agent)													
Nateglinide	0	1	3	3	3	3	1	0	2	3	4	1	2
Repaglinide	0	1	0	1	0	0	1	0	3	5	2	3	2

Table 3a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Sulfonylureas (Any Agent)	199	360	506	538	644	779	1,417	1,864	3,816	4,528	4,374	4,512	4,703
Sulfonylureas (Specific Agent)													
Acetohexamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Chlorpropamide	1	0	0	2	0	1	0	0	0	0	0	1	0
Glimepiride	1	6	7	5	16	13	18	15	21	49	48	45	36
Glipizide	11	18	21	13	21	25	51	55	85	134	103	108	123
Glyburide	182	322	468	508	611	738	1,348	1,794	3,728	4,374	4,248	4,383	4,565
Tolazamide	5	20	16	13	4	9	8	5	1	1	0	0	0
Tolbutamide	1	0	0	1	0	0	0	1	0	0	0	0	0
Thiazolidinediones (Any Agent)	7	34	39	66	64	70	106	83	112	117	89	52	35
Thiazolidinediones (Specific Agent)													
Pioglitazone	4	20	19	50	33	54	64	62	93	96	80	50	35
Rosiglitazone	4	14	21	18	32	24	44	22	20	21	9	3	0
Combination Products (Any Agent)	4	9	20	19	33	11	41	66	93	102	87	74	74
Combination Products (Specific Agent)													
Alogliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	1	0	2	0	5	5	3	6
Glyburide combination products	4	9	19	10	7	5	15	19	39	35	30	25	21
Linagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	3
Pioglitazone combination products	0	0	0	0	0	2	12	30	24	26	15	11	5
Repaglinide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Rosiglitazone combination products	0	0	1	10	27	3	15	12	12	7	8	0	0
Saxagliptin combination products	0	0	0	0	0	0	0	0	0	0	1	9	12
Sitagliptin combination products	0	0	0	0	0	0	0	7	19	30	30	27	28
Injectable Insulin Product (Any Agent)	745	1,177	1,206	1,303	1,258	1,281	2,190	2,441	4,427	5,008	4,586	4,509	4,345
Injectable Insulin Product (Specific Agent)													
Rapid-acting	588	968	963	1,052	979	1,030	1,661	1,872	3,331	3,772	3,422	3,277	3,044
Intermediate-acting	670	1,044	1,051	1,076	1,023	1,016	1,694	1,841	3,301	3,725	3,365	3,259	3,038
Long-acting	0	25	54	137	169	192	270	339	578	742	720	744	864
Other-acting	64	124	94	112	84	76	119	113	181	188	147	153	101

Table 3a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Non-Pregnant Cohort[1,2]													
Available unique episodes	41,870	62,345	62,310	61,544	64,573	68,056	122,674	146,443	246,203	275,835	263,694	252,272	227,785
Any Antidiabetic Agent	587	980	1,116	1,291	1,354	1,362	2,820	3,347	5,732	6,513	6,288	5,936	5,288
Specific Antidiabetic Agents													
Alpha-Glucosidase Inhibitors (Any Agent)	4	4	1	7	8	4	5	11	15	17	11	16	10
Alpha-Glucosidase Inhibitors (Specific Agent)													
Acarbose	1	0	0	6	4	4	2	6	13	13	7	14	10
Miglitol	3	4	1	1	4	0	3	5	2	4	4	2	0
Amylin Analog (Any Agent)	0	0	0	0	0	4	15	18	36	42	29	28	16
Amylin Analog (Specific Agent)													
Pramlintide	0	0	0	0	0	4	15	18	36	42	29	28	16
Biguanide (Any Agent)	269	490	649	814	896	913	2,011	2,434	4,188	4,801	4,667	4,445	3,941
Biguanide (Specific Agent)													
Metformin	269	490	649	814	896	913	2,011	2,434	4,188	4,801	4,667	4,445	3,941
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	1	26	65	122	111	169	158	121
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)													
Alogliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0	0	0	0	4	15	24
Saxagliptin	0	0	0	0	0	0	0	0	2	12	41	32	27
Sitagliptin	0	0	0	0	0	1	26	65	121	99	124	113	72
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	0	1	29	86	115	219	185	264	215	230
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)													
Exenatide	0	0	0	0	1	29	86	115	219	149	116	82	69
Liraglutide	0	0	0	0	0	0	0	0	0	41	162	138	170
Meglitinide Analogs (Any Agent)	0	4	8	19	11	12	15	10	22	13	15	17	10
Meglitinide Analogs (Specific Agent)													
Nateglinide	0	3	7	14	9	12	8	4	9	5	6	9	3
Repaglinide	0	1	1	5	2	1	7	6	13	8	9	8	7

Table 3a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Sulfonylureas (Any Agent)	191	286	252	307	287	262	406	424	682	726	676	613	571
Sulfonylureas (Specific Agent)													
Acetohexamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Chlorpropamide	0	0	0	1	0	1	0	0	0	2	1	0	0
Glimepiride	7	6	22	31	42	27	61	88	165	204	173	161	141
Glipizide	27	52	58	73	94	75	175	197	336	354	336	331	314
Glyburide	125	181	142	172	130	140	171	152	189	195	181	136	122
Tolazamide	42	54	41	39	32	29	17	4	8	1	0	0	1
Tolbutamide	0	2	0	0	1	0	0	0	0	0	1	1	0
Thiazolidinediones (Any Agent)	44	105	140	171	183	167	259	218	290	267	232	102	54
Thiazolidinediones (Specific Agent)													
Pioglitazone	27	62	84	99	103	138	189	187	252	231	220	102	54
Rosiglitazone	18	47	59	76	87	50	86	34	39	40	15	0	0
Combination Products (Any Agent)	13	34	34	53	69	38	114	142	292	303	238	222	154
Combination Products (Specific Agent)													
Alogliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	1	4	3	11	15	11	10	5
Glyburide combination products	13	34	28	18	10	10	32	47	68	61	53	41	26
Linagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	2	5
Pioglitazone combination products	0	0	0	0	0	8	42	42	64	90	52	33	10
Repaglinide combination products	0	0	0	0	0	0	0	0	0	2	0	0	0
Rosiglitazone combination products	0	0	8	37	59	20	38	34	33	29	13	1	0
Saxagliptin combination products	0	0	0	0	0	0	0	0	0	0	19	29	43
Sitagliptin combination products	0	0	0	0	0	0	4	21	121	117	100	117	69

Table 3a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Injectable Insulin Product (Any Agent)	272	409	427	443	452	470	774	866	1,438	1,650	1,562	1,520	1,380
Injectable Insulin Product (Specific Agent)													
Rapid-acting	217	312	340	342	357	376	604	677	1,135	1,296	1,221	1,206	1,084
Intermediate-acting	174	220	173	155	129	138	166	148	188	183	211	165	191
Long-acting	10	50	147	179	211	221	381	450	795	864	863	874	713
Other-acting	94	133	110	112	98	86	99	101	125	124	109	100	79

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 3b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Pregnant Cohort with Diabetes													
Available unique episodes	245	462	492	585	581	626	1,040	1,271	1,946	2,330	2,132	2,107	1,789
Any Antidiabetic Agent	234	434	466	549	521	582	958	1,170	1,809	2,168	1,952	1,957	1,688
Specific Antidiabetic Agents													
Alpha-Glucosidase Inhibitors (Any Agent)	0	1	0	0	0	2	3	6	6	3	1	3	3
Alpha-Glucosidase Inhibitors (Specific Agent)													
Acarbose	0	1	0	0	0	1	3	5	5	3	1	3	3
Miglitol	0	0	0	0	0	1	0	1	1	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0	4	6	8	11	4	5	6
Amylin Analog (Specific Agent)													
Pramlintide	0	0	0	0	0	0	4	6	8	11	4	5	6
Biguanide (Any Agent)	50	100	153	183	187	226	387	478	751	918	847	863	743
Biguanide (Specific Agent)													
Metformin	50	100	153	183	187	226	387	478	751	918	847	863	743
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	0	6	16	36	39	36	37	53
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)													
Alogliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0	0	0	0	0	2	4
Saxagliptin	0	0	0	0	0	0	0	0	0	0	6	6	15
Sitagliptin	0	0	0	0	0	0	6	16	36	39	30	29	34
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	0	0	1	23	34	61	42	39	50	66
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)													
Exenatide	0	0	0	0	0	1	23	34	61	41	21	20	25
Liraglutide	0	0	0	0	0	0	0	0	0	1	18	30	42
Meglitinide Analogs (Any Agent)	0	2	3	4	3	3	2	0	5	8	5	4	4
Meglitinide Analogs (Specific Agent)													
Nateglinide	0	1	3	3	3	3	1	0	2	3	3	1	2
Repaglinide	0	1	0	1	0	0	1	0	3	5	2	3	2

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Sulfonylureas (Any Agent)	52	105	116	104	123	122	174	215	317	413	381	380	301
Sulfonylureas (Specific Agent)													
Acetohexamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Glimepiride	1	5	7	4	14	12	15	13	18	42	45	42	33
Glipizide	9	16	16	12	18	17	37	44	65	106	77	88	91
Glyburide	38	70	85	79	95	89	119	156	244	290	275	269	192
Tolazamide	4	19	13	12	3	9	7	5	1	1	0	0	0
Tolbutamide	1	0	0	1	0	0	0	1	0	0	0	0	0
Thiazolidinediones (Any Agent)	6	31	36	61	60	61	99	76	102	107	79	51	31
Thiazolidinediones (Specific Agent)													
Pioglitazone	4	18	18	46	32	48	60	57	86	88	72	49	31
Rosiglitazone	3	13	19	17	29	20	41	20	17	19	7	3	0
Combination Products (Any Agent)	0	8	13	15	29	6	29	51	71	86	72	59	63
Combination Products (Specific Agent)													
Alogliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0	0	2	0	5	4	3	6
Glyburide combination products	0	8	13	7	4	1	9	12	24	24	22	12	12
Linagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	2
Pioglitazone combination products	0	0	0	0	0	2	8	25	20	23	14	10	5
Repaglinide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	9	26	3	12	12	11	7	6	0	0
Saxagliptin combination products	0	0	0	0	0	0	0	0	0	0	1	9	12
Sitagliptin combination products	0	0	0	0	0	0	0	4	17	28	27	26	27
Injectable Insulin Product (Any Agent)	220	399	424	492	434	492	768	923	1,432	1,734	1,530	1,566	1,382
Injectable Insulin Product (Specific Agent)													
Rapid-acting	207	379	404	474	405	469	713	856	1,339	1,586	1,425	1,439	1,276
Intermediate-acting	182	331	342	357	307	328	482	542	775	957	798	814	635
Long-acting	0	21	44	106	120	153	215	250	394	505	457	463	463
Other-acting	49	90	63	82	63	62	72	60	84	111	75	70	46

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Non-Pregnant Cohort[1,2] with Diabetes													
Available unique episodes	244	461	492	584	580	625	1,038	1,271	1,946	2,329	2,131	2,107	1,789
Any Antidiabetic Agent	214	431	473	548	541	570	957	1,178	1,778	2,160	1,951	1,953	1,652
Specific Antidiabetic Agents													
Alpha-Glucosidase Inhibitors (Any Agent)	2	0	1	5	3	2	2	2	3	10	5	8	7
Alpha-Glucosidase Inhibitors (Specific Agent)													
Acarbose	1	0	1	1	0	1	1	2	1	7	5	7	6
Miglitol	1	0	0	4	3	1	1	0	2	3	0	1	1
Amylin Analog (Any Agent)	0	0	0	0	1	4	8	21	26	33	16	24	17
Amylin Analog (Specific Agent)													
Pramlintide	0	0	0	0	1	4	8	21	26	33	16	24	17
Biguanide (Any Agent)	71	165	180	263	260	286	445	580	816	1,011	963	955	767
Biguanide (Specific Agent)													
Metformin	71	165	180	263	260	286	445	580	816	1,011	963	955	767
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	0	15	34	55	106	81	103	87
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)													
Alogliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0	0	0	0	1	10	11
Saxagliptin	0	0	0	0	0	0	0	0	0	12	13	26	18
Sitagliptin	0	0	0	0	0	0	15	34	55	94	68	72	63
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	0	0	13	64	70	110	112	124	132	137
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)													
Exenatide	0	0	0	0	0	13	64	70	110	103	62	48	45
Liraglutide	0	0	0	0	0	0	0	0	0	19	69	86	97
Meglitinide Analogs (Any Agent)	1	6	4	13	10	8	4	13	5	9	7	11	8
Meglitinide Analogs (Specific Agent)													
Nateglinide	0	4	3	10	10	7	3	8	2	5	4	4	3
Repaglinide	1	2	1	3	0	1	1	6	3	4	3	7	5

Table 3b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Sulfonylureas (Any Agent)	85	149	150	172	151	151	219	255	323	439	392	374	301
Sulfonylureas (Specific Agent)													
Acetohexamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Chlorpropamide	1	0	0	0	0	0	1	0	0	0	0	0	0
Glimepiride	2	9	10	16	23	13	42	47	73	119	101	94	66
Glipizide	9	28	35	44	42	55	97	129	170	221	218	199	184
Glyburide	58	86	86	93	72	73	78	87	85	108	75	89	54
Tolazamide	16	30	22	24	20	16	11	8	2	2	2	0	1
Tolbutamide	1	0	0	0	0	0	0	0	1	0	1	0	0
Thiazolidinediones (Any Agent)	21	66	87	108	126	96	141	129	152	190	126	86	29
Thiazolidinediones (Specific Agent)													
Pioglitazone	8	38	49	66	65	76	103	108	125	171	118	85	29
Rosiglitazone	14	30	41	46	68	31	42	23	27	20	8	1	0
Combination Products (Any Agent)	3	17	28	37	40	19	48	89	146	174	134	102	119
Combination Products (Specific Agent)													
Alogliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glipizide combination products	0	0	1	1	0	2	2	3	6	8	4	3	6
Glyburide combination products	3	17	22	17	5	3	12	24	35	47	27	17	16
Linagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	7
Pioglitazone combination products	0	0	0	0	0	4	17	34	41	40	35	14	9
Repaglinide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Rosiglitazone combination products	0	0	6	19	35	12	17	20	17	10	1	0	
Saxagliptin combination products	0	0	0	0	0	0	0	0	0	0	10	18	33
Sitagliptin combination products	0	0	0	0	0	0	5	19	44	72	53	53	52

Table 3b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Injectable Insulin Product (Any Agent)	122	259	268	308	280	317	525	595	953	1,176	1,023	1,042	911
Injectable Insulin Product (Specific Agent)													
Rapid-acting	102	202	217	247	221	254	420	488	776	920	816	855	718
Intermediate-acting	88	139	117	127	70	99	107	105	120	123	113	118	116
Long-acting	8	44	86	119	137	149	291	311	499	631	572	552	473
Other-acting	35	88	76	76	60	55	60	47	76	93	63	52	58

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Pregnant Cohort with Lupus													
Available unique episodes	25	54	41	52	69	59	136	171	324	359	375	331	327
Any Antidiabetic Agent													
Specific Antidiabetic Agents	4	3	3	2	3	1	7	9	12	24	21	14	23
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)													
Acarbose	0	0	0	0	0	0	0	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog (Specific Agent)													
Pramlintide	0	0	0	0	0	0	0	0	0	0	0	0	0
Biguanide (Any Agent)	2	1	0	0	1	0	1	3	6	6	9	4	6
Biguanide (Specific Agent)													
Metformin	2	1	0	0	1	0	1	3	6	6	9	4	6
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)													
Alogliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Sitagliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	0	0	0	0	1	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)													
Exenatide	0	0	0	0	0	0	0	1	0	0	0	0	0
Liraglutide	0	0	0	0	0	0	0	0	0	0	0	0	0
Meglitinide Analogs (Any Agent)	0	0	0	0	0	0	0	0	0	0	1	0	0
Meglitinide Analogs (Specific Agent)													
Nateglinide	0	0	0	0	0	0	0	0	0	0	0	0	0
Repaglinide	0	0	0	0	0	0	0	0	0	0	1	0	0

Table 3c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Sulfonylureas (Any Agent)	0	0	1	0	2	0	2	3	3	10	5	3	11
Sulfonylureas (Specific Agent)													
Acetohexamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Glimepiride	0	0	0	0	1	0	0	0	0	0	0	0	0
Glipizide	0	0	0	0	0	0	0	1	0	0	0	0	0
Glyburide	0	0	1	0	1	0	2	2	3	10	5	3	11
Tolazamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	0	0	0	0	1	0	0	1	0	0	1	0	0
Thiazolidinediones (Specific Agent)													
Pioglitazone	0	0	0	0	1	0	0	1	0	0	1	0	0
Rosiglitazone	0	0	0	0	0	0	0	0	0	0	0	0	0
Combination Products (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Combination Products (Specific Agent)													
Alogliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glyburide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Linagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Pioglitazone combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Repaglinide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Sitagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Injectable Insulin Product (Any Agent)	2	2	2	2	2	1	4	5	5	10	9	7	10
Injectable Insulin Product (Specific Agent)													
Rapid-acting	1	2	0	2	2	1	3	4	5	9	7	4	6
Intermediate-acting	2	2	1	2	0	1	4	4	5	5	4	5	8
Long-acting	0	0	0	0	0	0	0	1	1	2	1	1	1
Other-acting	0	0	1	0	0	0	1	0	0	0	0	0	0

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Non-Pregnant Cohort[1,2] with Lupus													
Available unique episodes	24	50	37	50	66	56	133	165	317	359	373	329	325
Any Antidiabetic Agent	0	2	3	2	1	0	5	3	10	7	12	16	10
Specific Antidiabetic Agents													
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)													
Acarbose	0	0	0	0	0	0	0	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog (Specific Agent)													
Pramlintide	0	0	0	0	0	0	0	0	0	0	0	0	0
Biguanide (Any Agent)	0	1	0	1	1	0	2	1	8	3	11	13	8
Biguanide (Specific Agent)													
Metformin	0	1	0	1	1	0	2	1	8	3	11	13	8
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	0	1	0	0	0	0	1	0
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)													
Alogliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Sitagliptin	0	0	0	0	0	0	1	0	0	0	0	1	0
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	2	2
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)													
Exenatide	0	0	0	0	0	0	0	0	0	0	0	0	1
Liraglutide	0	0	0	0	0	0	0	0	0	0	0	2	1
Meglitinide Analogs (Any Agent)	0	0	0	0	0	0	0	1	0	0	0	1	1
Meglitinide Analogs (Specific Agent)													
Nateglinide	0	0	0	0	0	0	0	1	0	0	0	1	1
Repaglinide	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 3c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Sulfonylureas (Any Agent)	0	0	0	0	0	0	0	0	1	1	2	5	1
Sulfonylureas (Specific Agent)													
Acetohexamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Glimepiride	0	0	0	0	0	0	0	0	0	0	0	2	1
Glipizide	0	0	0	0	0	0	0	0	1	0	1	2	0
Glyburide	0	0	0	0	0	0	0	0	0	1	1	1	0
Tolazamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	0	0	0	0	0	0	1	1	2	0	0	0	0
Thiazolidinediones (Specific Agent)													
Pioglitazone	0	0	0	0	0	0	0	1	2	0	0	0	0
Rosiglitazone	0	0	0	0	0	0	1	0	0	0	0	0	0
Combination Products (Any Agent)	0	0	0	0	0	0	0	1	2	0	0	0	0
Combination Products (Specific Agent)										0	0	0	0
Alogliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glyburide combination products	0	0	0	0	0	0	0	0	2	0	0	0	0
Linagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Pioglitazone combination products	0	0	0	0	0	0	0	1	1	0	0	0	0
Repaglinide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Sitagliptin combination products	0	1	3	1	0	0	2	1	2	4	3	4	3

Table 3c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Injectable Insulin Product (Any Agent)	0	1	3	1	0	0	2	1	2	4	3	4	3
Injectable Insulin Product (Specific Agent)													
Rapid-acting	0	0	3	1	0	0	1	1	0	3	2	4	3
Intermediate-acting	0	1	1	0	0	0	0	0	0	0	0	0	1
Long-acting	0	0	2	1	0	0	1	1	2	3	3	1	2
Other-acting	0	0	0	0	0	0	1	0	1	0	0	1	2

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 3d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Pregnant Cohort with MS													
Available unique episodes	21	33	37	40	62	54	159	171	298	358	325	313	326
Any Antidiabetic Agent													
Specific Antidiabetic Agents	2	1	0	0	2	2	8	6	9	20	20	24	15
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)													
Acarbose	0	0	0	0	0	0	0	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog (Specific Agent)													
Pramlintide	0	0	0	0	0	0	0	0	0	0	0	0	0
Biguanide (Any Agent)	2	1	0	0	2	1	4	2	5	6	4	8	6
Biguanide (Specific Agent)													
Metformin	2	1	0	0	2	1	4	2	5	6	4	8	6
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	0	1	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)													
Alogliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Sitagliptin	0	0	0	0	0	0	1	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)													
Exenatide	0	0	0	0	0	0	0	0	0	0	0	0	0
Liraglutide	0	0	0	0	0	0	0	0	0	0	0	0	0
Meglitinide Analogs (Any Agent)	0	0	0	0	1	0	0	0	0	0	0	0	0
Meglitinide Analogs (Specific Agent)													
Nateglinide	0	0	0	0	1	0	0	0	0	0	0	0	0
Repaglinide	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 3d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Sulfonylureas (Any Agent)	1	0	0	0	0	0	3	2	2	9	9	9	7
Sulfonylureas (Specific Agent)													
Acetohexamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Glimepiride	0	0	0	0	0	0	0	0	0	0	0	0	0
Glipizide	1	0	0	0	0	0	0	0	0	0	0	0	0
Glyburide	0	0	0	0	0	0	3	2	2	9	9	9	7
Tolazamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	0	0	0	0	1	0	0	0	0	0	1	0	0
Thiazolidinediones (Specific Agent)													
Pioglitazone	0	0	0	0	0	0	0	0	0	0	1	0	0
Rosiglitazone	0	0	0	0	1	0	0	0	0	0	0	0	0
Combination Products (Any Agent)	0	0	0	0	0	0	0	0	0	1	0	0	0
Combination Products (Specific Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Alogliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glyburide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Linagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Pioglitazone combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Repaglinide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Sitagliptin combination products	0	0	0	0	0	0	0	0	0	1	0	0	0
Injectable Insulin Product (Any Agent)	1	1	0	0	0	1	2	2	4	7	7	9	4
Injectable Insulin Product (Specific Agent)													
Rapid-acting	1	1	0	0	0	1	2	1	3	5	4	8	4
Intermediate-acting	1	1	0	0	0	1	1	1	4	6	4	6	4
Long-acting	0	0	0	0	0	1	0	0	0	2	2	1	0
Other-acting	0	0	0	0	0	0	0	2	0	0	2	0	0

Table 3d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Non-Pregnant Cohort[1,2] with MS													
Available unique episodes	21	32	35	39	59	53	156	169	295	355	323	309	323
Any Antidiabetic Agent	1	1	1	0	2	3	5	5	11	14	6	8	7
Specific Antidiabetic Agents													
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)													
Acarbose	0	0	0	0	0	0	0	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	2	0
Amylin Analog (Specific Agent)													
Pramlintide	0	0	0	0	0	0	0	0	0	0	0	2	0
Biguanide (Any Agent)	0	0	0	0	1	2	3	3	7	9	5	3	5
Biguanide (Specific Agent)													
Metformin	0	0	0	0	1	2	3	3	7	9	5	3	5
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)													
Alogliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Sitagliptin	0	0	0	0	0	0	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	0	0	0	0	1	0	1	0	3	1
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)													
Exenatide	0	0	0	0	0	0	0	1	0	1	0	1	0
Liraglutide	0	0	0	0	0	0	0	0	0	0	0	2	1
Meglitinide Analogs (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	0	0
Meglitinide Analogs (Specific Agent)													
Nateglinide	0	0	0	0	0	0	0	0	0	0	0	0	0
Repaglinide	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 3d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Sulfonylureas (Any Agent)	0	0	0	0	0	1	1	0	1	0	0	0	0
Sulfonylureas (Specific Agent)													
Acetohexamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Glimepiride	0	0	0	0	0	0	0	0	1	0	0	0	0
Glipizide	0	0	0	0	0	0	1	0	0	0	0	0	0
Glyburide	0	0	0	0	0	1	0	0	0	0	0	0	0
Tolazamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0	0	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	0	0	1	0	0	1	1	0	0	0	0	0	0
Thiazolidinediones (Specific Agent)													
Pioglitazone	0	0	1	0	0	1	0	0	0	0	0	0	0
Rosiglitazone	0	0	0	0	0	0	1	0	0	0	0	0	0
Combination Products (Any Agent)	0	0	0	0	0	0	0	0	0	0	0	1	0
Combination Products (Specific Agent)													
Alogliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Glyburide combination products	0	0	0	0	0	0	0	0	0	0	0	1	0
Linagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Pioglitazone combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Repaglinide combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0
Sitagliptin combination products	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 3d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Injectable Insulin Product (Any Agent)	1	1	1	0	1	1	3	2	3	4	2	3	2
Injectable Insulin Product (Specific Agent)													
Rapid-acting	1	1	1	0	1	1	3	2	3	4	2	2	2
Intermediate-acting	0	0	0	0	0	0	0	0	1	0	1	1	0
Long-acting	0	0	0	0	0	0	1	1	3	1	1	0	1
Other-acting	0	0	0	0	0	1	1	0	0	0	0	1	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 4a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Pregnant Cohort							
Available unique episodes	115,584	260,013	495,250	610,703	329,080	76,995	7,979
Any Antidiabetic Agent	1,004	5,227	18,775	30,327	20,788	5,874	681
Specific Antidiabetic Agents							
Alpha-Glucosidase Inhibitors (Any Agent)	4	10	31	54	30	18	2
Alpha-Glucosidase Inhibitors (Specific Agent)							
Acarbose	4	10	31	53	28	17	2
Miglitol	0	0	0	1	2	1	0
Amylin Analog (Any Agent)	1	4	15	19	6	3	0
Amylin Analog (Specific Agent)							
Pramlintide	1	4	15	19	6	3	0
Biguanide (Any Agent)	294	1,839	8,616	12,809	7,238	1,687	274
Biguanide (Specific Agent)							
Metformin	294	1,839	8,616	12,809	7,238	1,687	274
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	1	4	34	69	83	30	21
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)							
Alogliptin	0	0	0	0	0	0	0
Linagliptin	0	0	0	1	4	1	0
Saxagliptin	0	0	6	10	8	4	2
Sitagliptin	1	4	28	58	71	25	19
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	4	12	58	109	98	36	16
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)							
Exenatide	3	8	43	74	73	25	12
Liraglutide	1	4	15	36	25	11	4
Meglitinide Analogs (Any Agent)	1	8	8	13	9	3	2
Meglitinide Analogs (Specific Agent)							
Nateglinide	1	6	5	6	5	2	1
Repaglinide	0	2	3	7	4	1	1

Table 4a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Sulfonylureas (Any Agent)	237	1,452	5,542	10,151	8,012	2,570	276
Sulfonylureas (Specific Agent)							
Acetohexamide	0	0	0	0	0	0	0
Chlorpropamide	1	0	2	0	1	1	0
Glimepiride	5	22	31	77	98	27	20
Glipizide	8	46	155	232	214	82	31
Glyburide	224	1,394	5,374	9,880	7,711	2,460	226
Tolazamide	0	5	13	27	23	11	3
Tolbutamide	0	0	1	1	0	1	0
Thiazolidinediones (Any Agent)	17	69	208	268	196	73	43
Thiazolidinediones (Specific Agent)							
Pioglitazone	12	47	146	203	155	60	37
Rosiglitazone	7	25	66	69	43	15	7
Combination Products (Any Agent)	10	55	117	197	177	52	25
Combination Products (Specific Agent)							
Alogliptin combination products	0	0	0	0	0	0	0
Glipizide combination products	1	0	1	6	8	6	0
Glyburide combination products	5	24	51	74	56	18	10
Linagliptin combination products	0	0	0	2	0	1	0
Pioglitazone combination products	1	9	26	42	41	5	1
Repaglinide combination products	0	0	0	0	0	0	0
Rosiglitazone combination products	2	16	21	30	20	4	2
Saxagliptin combination products	0	0	1	7	8	3	3
Sitagliptin combination products	1	6	18	41	48	17	10
Injectable Insulin Product (Any Agent)	590	2,562	6,986	11,868	9,392	2,813	265
Injectable Insulin Product (Specific Agent)							
Rapid-acting	515	2,180	5,455	8,785	6,839	2,011	174
Intermediate-acting	368	1,706	4,999	9,003	7,529	2,334	164
Long-acting	182	589	1,126	1,460	1,085	327	65
Other-acting	54	218	340	482	337	108	17

Table 4a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Non-Pregnant Cohort[1,2]							
Available unique episodes	115,584	259,895	495,231	610,770	329,150	76,981	7,993
Any Antidiabetic Agent	1,478	3,890	9,579	15,217	9,476	2,581	393
Specific Antidiabetic Agents							
Alpha-Glucosidase Inhibitors (Any Agent)	2	11	20	35	30	12	3
Alpha-Glucosidase Inhibitors (Specific Agent)							
Acarbose	1	9	14	26	19	9	2
Miglitol	1	2	6	9	11	3	1
Amylin Analog (Any Agent)	5	12	41	70	39	16	5
Amylin Analog (Specific Agent)							
Pramlintide	5	12	41	70	39	16	5
Biguanide (Any Agent)	965	2,494	6,922	11,261	6,826	1,783	267
Biguanide (Specific Agent)							
Metformin	965	2,494	6,922	11,261	6,826	1,783	267
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	5	24	87	276	265	99	17
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)							
Alogliptin	0	0	0	0	0	0	0
Linagliptin	0	0	3	19	14	6	1
Saxagliptin	0	2	12	49	38	11	2
Sitagliptin	5	22	74	209	215	82	14
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	23	56	179	474	429	158	25
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)							
Exenatide	22	43	119	282	282	105	13
Liraglutide	1	15	63	200	160	59	13
Meglitinide Analogs (Any Agent)	8	16	29	45	35	21	2
Meglitinide Analogs (Specific Agent)							
Nateglinide	6	12	19	21	19	12	0
Repaglinide	2	5	10	24	16	9	2

Table 4a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Sulfonylureas (Any Agent)	58	323	866	1,937	1,724	653	122
Sulfonylureas (Specific Agent)							
Acetohexamide	0	0	0	0	0	0	0
Chlorpropamide	0	1	0	0	3	1	0
Glimepiride	16	82	168	383	311	137	31
Glipizide	19	107	319	831	800	294	52
Glyburide	27	146	375	679	570	200	39
Tolazamide	1	5	34	95	85	43	5
Tolbutamide	0	0	2	0	3	0	0
Thiazolidinediones (Any Agent)	64	271	370	679	574	227	47
Thiazolidinediones (Specific Agent)							
Pioglitazone	50	185	269	546	475	188	35
Rosiglitazone	17	93	122	150	114	42	13
Combination Products (Any Agent)	26	108	249	606	503	180	34
Combination Products (Specific Agent)							
Alogliptin combination products	0	0	0	0	0	0	0
Glipizide combination products	0	2	8	21	15	11	3
Glyburide combination products	5	36	66	155	127	42	10
Linagliptin combination products	1	0	0	2	3	1	0
Pioglitazone combination products	5	17	57	132	100	27	3
Repaglinide combination products	0	0	0	0	1	1	0
Rosiglitazone combination products	12	37	54	75	68	21	5
Saxagliptin combination products	1	4	11	34	25	15	1
Sitagliptin combination products	3	14	66	206	181	64	15

Table 4a. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Injectable Insulin Product (Any Agent)	566	1,430	2,573	3,765	2,458	749	122
Injectable Insulin Product (Specific Agent)							
Rapid-acting	495	1,229	2,146	2,978	1,760	480	79
Intermediate-acting	110	236	422	745	541	167	20
Long-acting	334	746	1,263	1,810	1,159	377	69
Other-acting	76	243	283	355	297	100	16

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 4b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Pregnant Cohort with Diabetes							
Available unique episodes	404	1,608	3,545	4,949	3,745	1,082	273
Any Antidiabetic Agent	365	1,419	3,262	4,635	3,536	1,010	261
Specific Antidiabetic Agents							
Alpha-Glucosidase Inhibitors (Any Agent)	0	2	8	9	3	4	2
Alpha-Glucosidase Inhibitors (Specific Agent)							
Acarbose	0	2	8	8	2	3	2
Miglitol	0	0	0	1	1	1	0
Amylin Analog (Any Agent)	1	3	14	17	6	3	0
Amylin Analog (Specific Agent)							
Pramlintide	1	3	14	17	6	3	0
Biguanide (Any Agent)	87	311	1,102	1,906	1,722	598	160
Biguanide (Specific Agent)							
Metformin	87	311	1,102	1,906	1,722	598	160
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	1	3	32	66	75	27	19
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)							
Alogliptin	0	0	0	0	0	0	0
Linagliptin	0	0	0	1	4	1	0
Saxagliptin	0	0	5	10	7	3	2
Sitagliptin	1	3	27	55	64	23	17
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	3	11	56	103	94	34	15
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)							
Exenatide	2	7	41	72	70	23	11
Liraglutide	1	4	15	32	24	11	4
Meglitinide Analogs (Any Agent)	1	7	8	13	9	3	2
Meglitinide Analogs (Specific Agent)							
Nateglinide	1	5	5	6	5	2	1
Repaglinide	0	2	3	7	4	1	1

Table 4b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Sulfonylureas (Any Agent)	28	184	512	907	833	255	84
Sulfonylureas (Specific Agent)							
Acetohexamide	0	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0	0
Glimepiride	3	18	27	72	88	24	19
Glipizide	5	33	117	176	172	65	28
Glyburide	21	143	375	682	577	165	38
Tolazamide	0	4	11	25	22	9	3
Tolbutamide	0	0	1	1	0	1	0
Thiazolidinediones (Any Agent)	14	64	181	246	187	68	40
Thiazolidinediones (Specific Agent)							
Pioglitazone	12	43	126	191	147	56	34
Rosiglitazone	4	24	58	59	42	14	7
Combination Products (Any Agent)	6	37	84	155	155	43	22
Combination Products (Specific Agent)							
Alogliptin combination products	0	0	0	0	0	0	0
Glipizide combination products	1	0	1	5	7	6	0
Glyburide combination products	1	9	25	48	45	11	9
Linagliptin combination products	0	0	0	1	0	1	0
Pioglitazone combination products	1	9	21	35	37	4	0
Repaglinide combination products	0	0	0	0	0	0	0
Rosiglitazone combination products	2	15	19	26	18	4	2
Saxagliptin combination products	0	0	1	7	8	3	3
Sitagliptin combination products	1	4	18	37	44	16	9
Injectable Insulin Product (Any Agent)	321	1,237	2,701	3,767	2,868	789	113
Injectable Insulin Product (Specific Agent)							
Rapid-acting	305	1,189	2,573	3,511	2,617	702	75
Intermediate-acting	147	629	1,388	2,169	1,912	563	42
Long-acting	156	458	794	904	638	191	50
Other-acting	44	155	208	263	187	56	14

Table 4b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Non-Pregnant Cohort[1,2] with Diabetes							
Available unique episodes	404	1,606	3,538	4,947	3,747	1,082	273
Any Antidiabetic Agent	382	1,470	3,269	4,523	3,486	1,012	264
Specific Antidiabetic Agents							
Alpha-Glucosidase Inhibitors (Any Agent)	0	1	10	19	12	7	1
Alpha-Glucosidase Inhibitors (Specific Agent)							
Acarbose	0	1	5	13	8	6	0
Miglitol	0	0	5	6	4	1	1
Amylin Analog (Any Agent)	2	13	45	59	27	4	0
Amylin Analog (Specific Agent)							
Pramlintide	2	13	45	59	27	4	0
Biguanide (Any Agent)	128	440	1,256	2,212	1,949	608	169
Biguanide (Specific Agent)							
Metformin	128	440	1,256	2,212	1,949	608	169
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	2	16	72	138	158	70	25
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)							
Alogliptin	0	0	0	0	0	0	0
Linagliptin	0	0	2	9	6	4	1
Saxagliptin	1	3	2	28	19	13	3
Sitagliptin	1	13	68	105	137	55	22
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	7	41	136	232	258	70	18
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)							
Exenatide	6	30	95	162	163	48	11
Liraglutide	1	11	45	82	101	24	7
Meglitinide Analogs (Any Agent)	2	11	19	36	20	5	6
Meglitinide Analogs (Specific Agent)							
Nateglinide	2	8	17	17	12	2	5
Repaglinide	0	4	2	19	8	3	1

Table 4b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Sulfonylureas (Any Agent)	20	156	496	1,053	981	357	98
Sulfonylureas (Specific Agent)							
Acetohexamide	0	0	0	0	0	0	0
Chlorpropamide	0	0	1	1	0	0	0
Glimepiride	6	41	105	190	177	69	27
Glipizide	2	47	202	468	488	177	47
Glyburide	13	71	192	355	290	102	21
Tolazamide	0	4	11	64	52	18	5
Tolbutamide	0	1	0	0	1	1	0
Thiazolidinediones (Any Agent)	18	144	248	399	388	117	43
Thiazolidinediones (Specific Agent)							
Pioglitazone	12	101	184	299	307	100	38
Rosiglitazone	7	51	71	108	89	20	5
Combination Products (Any Agent)	7	52	167	308	285	109	28
Combination Products (Specific Agent)							
Alogliptin combination products	0	0	0	0	0	0	0
Glipizide combination products	0	1	7	10	13	4	1
Glyburide combination products	4	19	44	74	66	29	9
Linagliptin combination products	0	0	1	3	2	0	1
Pioglitazone combination products	0	9	37	73	49	21	5
Repaglinide combination products	0	0	0	0	0	0	0
Rosiglitazone combination products	2	14	34	46	46	12	6
Saxagliptin combination products	0	1	10	21	24	3	2
Sitagliptin combination products	1	10	41	96	100	46	4

Table 4b. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Diabetes by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Injectable Insulin Product (Any Agent)	277	1,073	2,088	2,341	1,556	377	67
Injectable Insulin Product (Specific Agent)							
Rapid-acting	257	951	1,791	1,842	1,126	239	30
Intermediate-acting	60	157	328	466	343	79	9
Long-acting	161	548	1,044	1,117	756	201	45
Other-acting	39	150	194	233	167	46	10

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 4c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Pregnant Cohort with Lupus							
Available unique episodes	49	227	544	845	512	127	19
Any Antidiabetic Agent	2	10	22	44	36	10	2
Specific Antidiabetic Agents							
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)							
Acarbose	0	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0	0
Amylin Analog (Specific Agent)							
Pramlintide	0	0	0	0	0	0	0
Biguanide (Any Agent)	0	4	6	13	12	3	1
Biguanide (Specific Agent)							
Metformin	0	4	6	13	12	3	1
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)							
Alogliptin	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0	0
Sitagliptin	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	1	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)							
Exenatide	0	0	0	1	0	0	0
Liraglutide	0	0	0	0	0	0	0
Meglitinide Analogs (Any Agent)	0	0	0	1	0	0	0
Meglitinide Analogs (Specific Agent)							
Nateglinide	0	0	0	0	0	0	0
Repaglinide	0	0	0	1	0	0	0

Table 4c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Sulfonylureas (Any Agent)	0	4	5	17	10	4	0
Sulfonylureas (Specific Agent)							
Acetohexamide	0	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0	0
Glimepiride	0	1	0	0	0	0	0
Glipizide	0	1	0	0	0	0	0
Glyburide	0	2	5	17	10	4	0
Tolazamide	0	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	0	1	0	1	1	0	0
Thiazolidinediones (Specific Agent)							
Pioglitazone	0	1	0	1	1	0	0
Rosiglitazone	0	0	0	0	0	0	0
Combination Products (Any Agent)	0	0	0	0	0	0	0
Combination Products (Specific Agent)							
Alogliptin combination products	0	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0	0
Glyburide combination products	0	0	0	0	0	0	0
Linagliptin combination products	0	0	0	0	0	0	0
Pioglitazone combination products	0	0	0	0	0	0	0
Repaglinide combination products	0	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0	0
Sitagliptin combination products	0	0	0	0	0	0	0
Injectable Insulin Product (Any Agent)	2	3	12	19	20	3	2
Injectable Insulin Product (Specific Agent)							
Rapid-acting	1	3	8	14	17	3	0
Intermediate-acting	2	2	10	12	14	2	1
Long-acting	1	0	0	4	1	0	1
Other-acting	0	0	1	1	0	0	0

Table 4c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Non-Pregnant Cohort[1,2] with Lupus							
Available unique episodes	43	221	532	836	507	126	19
Any Antidiabetic Agent	1	3	13	29	17	6	2
Specific Antidiabetic Agents							
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)							
Acarbose	0	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0	0
Amylin Analog (Specific Agent)							
Pramlintide	0	0	0	0	0	0	0
Biguanide (Any Agent)	0	2	5	23	14	3	2
Biguanide (Specific Agent)							
Metformin	0	2	5	23	14	3	2
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	1	0	1
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)							
Alogliptin	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0	0
Sitagliptin	0	0	0	0	1	0	1
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	2	1	0	1
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)							
Exenatide	0	0	0	1	0	0	0
Liraglutide	0	0	0	1	1	0	1
Meglitinide Analogs (Any Agent)	0	0	0	0	2	1	0
Meglitinide Analogs (Specific Agent)							
Nateglinide	0	0	0	0	2	1	0
Repaglinide	0	0	0	0	0	0	0

Table 4c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Sulfonylureas (Any Agent)	0	0	0	6	1	3	0
Sulfonylureas (Specific Agent)							
Acetohexamide	0	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0	0
Glimepiride	0	0	0	2	0	1	0
Glipizide	0	0	0	2	0	2	0
Glyburide	0	0	0	2	1	0	0
Tolazamide	0	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	0	0	1	1	2	0	0
Thiazolidinediones (Specific Agent)							
Pioglitazone	0	0	1	1	1	0	0
Rosiglitazone	0	0	0	0	1	0	0
Combination Products (Any Agent)	0	0	1	1	1	0	0
Combination Products (Specific Agent)							
Alogliptin combination products	0	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0	0
Glyburide combination products	0	0	1	0	1	0	0
Linagliptin combination products	0	0	0	0	0	0	0
Pioglitazone combination products	0	0	0	1	1	0	0
Repaglinide combination products	0	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0	0
Sitagliptin combination products	0	0	0	0	1	0	0

Table 4c. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Lupus by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Injectable Insulin Product (Any Agent)	1	1	8	8	4	2	0
Injectable Insulin Product (Specific Agent)							
Rapid-acting	1	0	6	5	4	2	0
Intermediate-acting	0	0	2	0	1	0	0
Long-acting	1	1	4	5	4	1	0
Other-acting	0	1	1	2	1	0	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Pregnant Cohort with MS							
Available unique episodes	17	117	453	891	567	132	20
Any Antidiabetic Agent	0	3	12	50	35	9	0
Specific Antidiabetic Agents							
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)							
Acarbose	0	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	0	0	0
Amylin Analog (Specific Agent)							
Pramlintide	0	0	0	0	0	0	0
Biguanide (Any Agent)	0	1	7	22	9	2	0
Biguanide (Specific Agent)							
Metformin	0	1	7	22	9	2	0
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	1	0	0
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)							
Alogliptin	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0	0
Sitagliptin	0	0	0	0	1	0	0
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)							
Exenatide	0	0	0	0	0	0	0
Liraglutide	0	0	0	0	0	0	0
Meglitinide Analogs (Any Agent)	0	0	0	0	0	1	0
Meglitinide Analogs (Specific Agent)							
Nateglinide	0	0	0	0	0	1	0
Repaglinide	0	0	0	0	0	0	0

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Sulfonylureas (Any Agent)	0	0	4	18	16	4	0
Sulfonylureas (Specific Agent)							
Acetohexamide	0	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0	0
Glimepiride	0	0	0	0	0	0	0
Glipizide	0	0	0	1	0	0	0
Glyburide	0	0	4	17	16	4	0
Tolazamide	0	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	0	0	0	0	1	1	0
Thiazolidinediones (Specific Agent)							
Pioglitazone	0	0	0	0	1	0	0
Rosiglitazone	0	0	0	0	0	1	0
Combination Products (Any Agent)	0	0	0	1	0	0	0
Combination Products (Specific Agent)							
Alogliptin combination products	0	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0	0
Glyburide combination products	0	0	0	0	0	0	0
Linagliptin combination products	0	0	0	0	0	0	0
Pioglitazone combination products	0	0	0	0	0	0	0
Repaglinide combination products	0	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0	0
Sitagliptin combination products	0	0	0	1	0	0	0
Injectable Insulin Product (Any Agent)	0	2	2	16	13	5	0
Injectable Insulin Product (Specific Agent)							
Rapid-acting	0	2	2	12	9	5	0
Intermediate-acting	0	1	2	11	10	5	0
Long-acting	0	2	0	3	1	0	0
Other-acting	0	0	0	2	2	0	0

Table 4d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Non-Pregnant Cohort[1,2] with MS							
Available unique episodes	15	105	444	887	566	132	20
Any Antidiabetic Agent	1	2	10	21	26	3	1
Specific Antidiabetic Agents							
Alpha-Glucosidase Inhibitors (Any Agent)	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors (Specific Agent)							
Acarbose	0	0	0	0	0	0	0
Miglitol	0	0	0	0	0	0	0
Amylin Analog (Any Agent)	0	0	0	0	2	0	0
Amylin Analog (Specific Agent)							
Pramlintide	0	0	0	0	2	0	0
Biguanide (Any Agent)	1	1	6	11	17	2	0
Biguanide (Specific Agent)							
Metformin	1	1	6	11	17	2	0
Dipeptidyl Peptidase-4 Inhibitors (Any Agent)	0	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors (Specific Agent)							
Alogliptin	0	0	0	0	0	0	0
Linagliptin	0	0	0	0	0	0	0
Saxagliptin	0	0	0	0	0	0	0
Sitagliptin	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists (Any Agent)	0	0	2	2	2	0	0
Glucagon-like Peptide-1 Receptor Agonists (Specific Agent)							
Exenatide	0	0	0	1	2	0	0
Liraglutide	0	0	2	1	0	0	0
Meglitinide Analogs (Any Agent)	0	0	0	0	0	0	0
Meglitinide Analogs (Specific Agent)							
Nateglinide	0	0	0	0	0	0	0
Repaglinide	0	0	0	0	0	0	0

Table 4d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Sulfonylureas (Any Agent)	0	0	0	0	3	0	0
Sulfonylureas (Specific Agent)							
Acetohexamide	0	0	0	0	0	0	0
Chlorpropamide	0	0	0	0	0	0	0
Glimepiride	0	0	0	0	1	0	0
Glipizide	0	0	0	0	1	0	0
Glyburide	0	0	0	0	1	0	0
Tolazamide	0	0	0	0	0	0	0
Tolbutamide	0	0	0	0	0	0	0
Thiazolidinediones (Any Agent)	1	0	0	1	1	0	0
Thiazolidinediones (Specific Agent)							
Pioglitazone	0	0	0	1	1	0	0
Rosiglitazone	1	0	0	0	0	0	0
Combination Products (Any Agent)	0	0	0	1	0	0	0
Combination Products (Specific Agent)							
Alogliptin combination products	0	0	0	0	0	0	0
Glipizide combination products	0	0	0	0	0	0	0
Glyburide combination products	0	0	0	1	0	0	0
Linagliptin combination products	0	0	0	0	0	0	0
Pioglitazone combination products	0	0	0	0	0	0	0
Repaglinide combination products	0	0	0	0	0	0	0
Rosiglitazone combination products	0	0	0	0	0	0	0
Saxagliptin combination products	0	0	0	0	0	0	0
Sitagliptin combination products	0	0	0	0	0	0	0

Table 4d. Prevalence of Medication Use of the Pregnant Cohort and Non-Pregnant Cohort[1,2] with Pre-Existing Condition of Multiple Sclerosis (MS) by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Injectable Insulin Product (Any Agent)	0	1	4	7	10	1	1
Injectable Insulin Product (Specific Agent)							
Rapid-acting	0	1	4	7	9	1	1
Intermediate-acting	0	0	1	1	1	0	0
Long-acting	0	1	0	4	2	1	0
Other-acting	0	0	0	0	3	0	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 5a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Pregnant Cohort						
No use of any ADA at any time during pregnancy	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	46,674	6,034	11,958	43,693	3,336
Episodes among members with gestational diabetes diagnoses #1	0	40,095	1,913	7,916	39,335	1,331
Episodes among members with gestational diabetes diagnoses #2	0	43,004	3,343	10,023	42,027	2,561
Episodes among members with gestational diabetes diagnoses #3	0	43,109	3,423	10,112	42,114	2,625
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	3,565	2,611	1,846	1,579	711
Alpha-Glucosidase Inhibitors	0	115	3	9	111	0
Episodes among members with gestational diabetes diagnoses #1	0	108	1	7	107	0
Episodes among members with gestational diabetes diagnoses #2	0	111	2	8	109	0
Episodes among members with gestational diabetes diagnoses #3	0	111	2	8	109	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	4	1	1	2	0
Amylin Analog	0	4	4	1	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	2	2	1	0	0
Episodes among members with gestational diabetes diagnoses #3	0	2	2	1	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	2	2	0	0	0

Table 5a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Biguanide	0	6,074	3,318	2,245	3,240	603
Episodes among members with gestational diabetes diagnoses #1	0	3,026	803	789	2,356	180
Episodes among members with gestational diabetes diagnoses #2	0	3,535	1,143	1,101	2,628	296
Episodes among members with gestational diabetes diagnoses #3	0	3,556	1,161	1,114	2,634	300
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	2,518	2,157	1,131	606	303
Combination Products	0	124	37	35	79	4
Episodes among members with gestational diabetes diagnoses #1	0	65	5	13	55	1
Episodes among members with gestational diabetes diagnoses #2	0	84	16	20	63	3
Episodes among members with gestational diabetes diagnoses #3	0	84	16	20	63	3
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	40	21	15	16	1
Dipeptidyl Peptidase-4 Inhibitors	0	15	11	5	6	2
Episodes among members with gestational diabetes diagnoses #1	0	4	3	1	2	1
Episodes among members with gestational diabetes diagnoses #2	0	8	6	1	3	1
Episodes among members with gestational diabetes diagnoses #3	0	8	6	1	3	1
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	7	5	4	3	1
Glucagon-like Peptide-1 Receptor Agonists	0	13	8	7	2	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	5	5	2	0	0
Episodes among members with gestational diabetes diagnoses #3	0	5	5	2	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	8	3	5	2	0

Table 5a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Insulin	0	20,925	2,275	6,352	20,411	2,023
Episodes among members with gestational diabetes diagnoses #1	0	17,908	796	4,085	17,640	731
Episodes among members with gestational diabetes diagnoses #2	0	19,976	1,804	5,626	19,562	1,616
Episodes among members with gestational diabetes diagnoses #3	0	20,057	1,864	5,699	19,634	1,669
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	868	411	653	777	354
Meglitinide Analogs	0	1	1	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	1	0	0	0
Sulfonylureas	0	23,914	719	4,329	23,390	452
Episodes among members with gestational diabetes diagnoses #1	0	22,523	360	3,599	22,218	270
Episodes among members with gestational diabetes diagnoses #2	0	23,519	628	4,148	23,062	416
Episodes among members with gestational diabetes diagnoses #3	0	23,539	636	4,160	23,079	422
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	375	83	169	311	30
Thiazolidinediones	0	53	36	12	17	2
Episodes among members with gestational diabetes diagnoses #1	0	9	6	2	3	0
Episodes among members with gestational diabetes diagnoses #2	0	16	13	2	3	0
Episodes among members with gestational diabetes diagnoses #3	0	16	13	2	3	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	37	23	10	14	2

Table 5a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Non-Pregnant Cohort[1,2]						
No use of any ADA at any time during pregnancy	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	11,610	4,067	6,989	8,969	2,104
Episodes among members with gestational diabetes diagnoses #1	0	137	18	63	113	2
Episodes among members with gestational diabetes diagnoses #2	0	150	25	71	120	5
Episodes among members with gestational diabetes diagnoses #3	0	182	53	94	136	17
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	11,428	4,014	6,895	8,833	2,087
Alpha-Glucosidase Inhibitors	0	38	11	17	26	2
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	38	11	17	26	2
Amylin Analog	0	9	4	5	5	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	9	4	5	5	0

Table 5a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Biguanide	0	10,152	3,467	6,044	7,746	1,700
Episodes among members with gestational diabetes diagnoses #1	0	41	5	15	35	1
Episodes among members with gestational diabetes diagnoses #2	0	46	7	18	39	3
Episodes among members with gestational diabetes diagnoses #3	0	63	20	33	52	12
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	10,089	3,447	6,011	7,694	1,688
Combination Products	0	291	96	160	209	38
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	1	0	1	0	0
Episodes among members with gestational diabetes diagnoses #3	0	2	1	1	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	289	95	159	209	38
Dipeptidyl Peptidase-4 Inhibitors	0	122	38	65	91	18
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	2	0	1	1	0
Episodes among members with gestational diabetes diagnoses #3	0	4	0	3	3	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	118	38	62	88	18
Glucagon-like Peptide-1 Receptor Agonists	0	192	49	101	138	17
Episodes among members with gestational diabetes diagnoses #1	0	2	1	0	2	0
Episodes among members with gestational diabetes diagnoses #2	0	2	1	0	2	0
Episodes among members with gestational diabetes diagnoses #3	0	2	1	0	2	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	190	48	101	136	17

Table 5a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Insulin	0	866	305	520	645	159
Episodes among members with gestational diabetes diagnoses #1	0	49	9	23	35	0
Episodes among members with gestational diabetes diagnoses #2	0	57	13	27	39	1
Episodes among members with gestational diabetes diagnoses #3	0	61	17	30	40	2
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	805	288	490	605	157
Meglitinide Analogs	0	17	5	8	15	3
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	17	5	8	15	3
Sulfonylureas	0	955	303	536	741	146
Episodes among members with gestational diabetes diagnoses #1	0	61	4	29	52	1
Episodes among members with gestational diabetes diagnoses #2	0	64	6	31	53	1
Episodes among members with gestational diabetes diagnoses #3	0	75	17	36	54	2
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	880	286	500	687	144
Thiazolidinediones	0	300	99	154	226	44
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	300	99	154	226	44

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 5b. Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Pregnant Cohort with Diabetes						
No use of any ADA at any time during pregnancy	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5b. Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Biguanide	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Combination Products	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5b. Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Insulin	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Meglitinide Analogs	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Sulfonylureas	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Thiazolidinediones	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5b. Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Non-Pregnant Cohort[1,2] with Diabetes						
No use of any ADA at any time during pregnancy	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5b. Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Biguanide	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Combination Products	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5b. Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Insulin	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Meglitinide Analogs	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Sulfonylureas	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Thiazolidinediones	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 5c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Pregnant Cohort with Lupus						
No use of any ADA at any time during pregnancy	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	71	6	24	65	1
Episodes among members with gestational diabetes diagnoses #1	0	61	1	20	59	0
Episodes among members with gestational diabetes diagnoses #2	0	66	2	22	64	1
Episodes among members with gestational diabetes diagnoses #3	0	66	2	22	64	1
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	5	4	2	1	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Biguanide	0	8	4	3	4	0
Episodes among members with gestational diabetes diagnoses #1	0	5	1	2	4	0
Episodes among members with gestational diabetes diagnoses #2	0	5	1	2	4	0
Episodes among members with gestational diabetes diagnoses #3	0	5	1	2	4	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	3	3	1	0	0
Combination Products	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Insulin	0	38	2	16	36	1
Episodes among members with gestational diabetes diagnoses #1	0	34	0	14	33	0
Episodes among members with gestational diabetes diagnoses #2	0	37	1	16	36	1
Episodes among members with gestational diabetes diagnoses #3	0	37	1	16	36	1
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	1	0	0	0
Meglitinide Analogs	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Sulfonylureas	0	32	0	6	31	0
Episodes among members with gestational diabetes diagnoses #1	0	29	0	5	28	0
Episodes among members with gestational diabetes diagnoses #2	0	31	0	5	30	0
Episodes among members with gestational diabetes diagnoses #3	0	31	0	5	30	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	1	1	0
Thiazolidinediones	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Non-Pregnant Cohort[1,2] with Lupus						
No use of any ADA at any time during pregnancy	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	11	2	5	8	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	11	2	5	8	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Biguanide	0	10	2	4	7	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	10	2	4	7	0
Combination Products	0	1	0	1	1	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	1	1	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Insulin	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Meglitinide Analogs	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Sulfonylureas	0	1	0	1	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	1	0	0
Thiazolidinediones	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 5d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Pregnant Cohort with MS						
No use of any ADA at any time during pregnancy	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	58	6	12	56	4
Episodes among members with gestational diabetes diagnoses #1	0	51	1	8	51	1
Episodes among members with gestational diabetes diagnoses #2	0	55	3	10	55	3
Episodes among members with gestational diabetes diagnoses #3	0	55	3	10	55	3
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	3	3	2	1	1
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Biguanide	0	6	3	2	4	1
Episodes among members with gestational diabetes diagnoses #1	0	2	0	0	2	0
Episodes among members with gestational diabetes diagnoses #2	0	3	0	0	3	0
Episodes among members with gestational diabetes diagnoses #3	0	3	0	0	3	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	3	3	2	1	1
Combination Products	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Insulin	0	19	0	3	19	0
Episodes among members with gestational diabetes diagnoses #1	0	19	0	3	19	0
Episodes among members with gestational diabetes diagnoses #2	0	19	0	3	19	0
Episodes among members with gestational diabetes diagnoses #3	0	19	0	3	19	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Meglitinide Analogs	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Sulfonylureas	0	35	3	7	35	3
Episodes among members with gestational diabetes diagnoses #1	0	31	1	5	31	1
Episodes among members with gestational diabetes diagnoses #2	0	35	3	7	35	3
Episodes among members with gestational diabetes diagnoses #3	0	35	3	7	35	3
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Thiazolidinediones	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Non-Pregnant Cohort[1,2] with MS						
No use of any ADA at any time during pregnancy	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	15	5	9	13	4
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	15	5	9	13	4
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0

Table 5d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Biguanide	0	12	4	7	10	3
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	12	4	7	10	3
Combination Products	0	1	0	1	1	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	1	1	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	1	0	1	1	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	1	1	0

Table 5d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Trimester

	Use in the 90 Days Before Pregnancy	Any Use During Pregnancy	Any Use, First Trimester	Any Use, Second Trimester	Any Use, Third Trimester	Use in First, Second, and Third Trimester
Insulin	0	1	0	0	1	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	0	1	0
Meglitinide Analogs	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0
Sulfonylureas	0	1	1	1	1	1
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	1	1	1	1
Thiazolidinediones	0	1	1	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	1	0	0	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 6a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Pregnant Cohort													
No use of any ADA at any time during pregnancy	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	648	970	1,126	1,186	1,280	1,352	2,600	3,100	6,342	7,180	6,918	6,913	7,059
Episodes among members with gestational diabetes diagnoses #1	548	826	971	1,011	1,103	1,146	2,192	2,615	5,423	6,171	5,915	5,979	6,195
Episodes among members with gestational diabetes diagnoses #2	604	909	1,059	1,100	1,189	1,239	2,355	2,826	5,835	6,621	6,335	6,362	6,570
Episodes among members with gestational diabetes diagnoses #3	607	913	1,060	1,103	1,192	1,244	2,360	2,840	5,848	6,630	6,355	6,374	6,583
Episodes among members without gestational diabetes diagnosis during pregnancy episode	41	57	66	83	88	108	240	260	494	550	563	539	476
Alpha-Glucosidase Inhibitors	2	0	0	0	0	0	6	19	13	20	20	17	18
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	6	19	10	20	20	15	18
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	6	19	11	20	20	17	18
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	6	19	11	20	20	17	18
Episodes among members without gestational diabetes diagnosis during pregnancy episode	2	0	0	0	0	0	0	0	2	0	0	0	0
Amylin Analog	0	0	0	0	0	0	0	0	2	0	1	1	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	1	0	1	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	1	0	1	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	1	0	0	1	0

Table 6a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Biguanide	21	31	68	90	114	114	296	419	886	1,033	1,050	1,025	927
Episodes among members with gestational diabetes diagnoses #1	3	8	24	32	51	48	106	186	435	534	547	549	503
Episodes among members with gestational diabetes diagnoses #2	7	13	31	44	66	59	129	227	514	613	626	628	578
Episodes among members with gestational diabetes diagnoses #3	7	13	31	44	67	59	130	231	516	614	632	631	581
Episodes among members without gestational diabetes diagnosis during pregnancy episode	14	18	37	46	47	55	166	188	370	419	418	394	346
Combination Products	4	1	7	4	3	4	10	15	21	16	15	13	11
Episodes among members with gestational diabetes diagnoses #1	0	0	4	1	2	1	4	10	10	9	11	6	7
Episodes among members with gestational diabetes diagnoses #2	0	1	5	2	2	1	5	11	15	12	12	10	8
Episodes among members with gestational diabetes diagnoses #3	0	1	5	2	2	1	5	11	15	12	12	10	8
Episodes among members without gestational diabetes diagnosis during pregnancy episode	4	0	2	2	1	3	5	4	6	4	3	3	3
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0	0	4	1	1	3	4	2
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	1	0	0	0	1	2
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	3	0	0	1	2	2
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	3	0	0	1	2	2
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	1	1	1	2	2	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	1	1	2	1	1	3	3	1
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	1	1	0	1	2	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	1	1	0	1	2	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	1	0	1	1	0	1	3	1
Insulin	512	754	750	773	769	736	1,310	1,381	2,744	2,967	2,808	2,713	2,708
Episodes among members with gestational diabetes diagnoses #1	436	640	651	665	661	615	1,122	1,182	2,365	2,529	2,371	2,340	2,331
Episodes among members with gestational diabetes diagnoses #2	489	714	730	735	730	691	1,246	1,318	2,640	2,846	2,662	2,579	2,596
Episodes among members with gestational diabetes diagnoses #3	492	718	731	738	733	694	1,250	1,327	2,650	2,854	2,677	2,588	2,605
Episodes among members without gestational diabetes diagnosis during pregnancy episode	20	36	19	35	36	42	60	54	94	113	131	125	103

Table 6a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Meglitinide Analogs	0	0	0	0	0	0	0	0	0	0	1	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	1	0	0
Sulfonylureas	147	247	386	420	505	623	1,169	1,544	3,295	3,850	3,718	3,887	4,123
Episodes among members with gestational diabetes diagnoses #1	132	220	357	385	477	577	1,095	1,448	3,095	3,638	3,521	3,663	3,915
Episodes among members with gestational diabetes diagnoses #2	139	235	377	409	495	602	1,143	1,520	3,248	3,796	3,669	3,826	4,060
Episodes among members with gestational diabetes diagnoses #3	139	235	377	409	495	605	1,144	1,523	3,252	3,797	3,672	3,829	4,062
Episodes among members without gestational diabetes diagnosis during pregnancy episode	8	12	9	11	10	18	25	21	43	53	46	58	61
Thiazolidinediones	0	1	3	4	2	7	6	5	8	8	5	1	3
Episodes among members with gestational diabetes diagnoses #1	0	0	1	1	0	2	1	0	1	1	0	0	2
Episodes among members with gestational diabetes diagnoses #2	0	0	1	2	1	2	1	1	2	4	0	0	2
Episodes among members with gestational diabetes diagnoses #3	0	0	1	2	1	2	1	1	2	4	0	0	2
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	2	2	1	5	5	4	6	4	5	1	1

Table 6a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Non-Pregnant Cohort[1,2]													
No use of any ADA at any time during pregnancy	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	139	208	265	303	354	333	738	899	1,600	1,859	1,744	1,642	1,526
Episodes among members with gestational diabetes diagnoses #1	2	4	3	1	1	2	7	6	16	13	18	17	47
Episodes among members with gestational diabetes diagnoses #2	4	4	3	2	1	2	7	7	18	16	21	18	47
Episodes among members with gestational diabetes diagnoses #3	5	4	5	2	1	3	10	8	25	23	25	21	50
Episodes among members without gestational diabetes diagnosis during pregnancy episode	134	204	260	301	353	330	728	891	1,575	1,836	1,719	1,621	1,476
Alpha-Glucosidase Inhibitors	2	1	0	5	1	1	2	1	2	10	3	5	5
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	2	1	0	5	1	1	2	1	2	10	3	5	5
Amylin Analog	0	0	0	0	0	0	1	0	2	3	1	2	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	1	0	2	3	1	2	0

Table 6a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Biguanide	85	147	205	236	293	273	652	804	1,430	1,651	1,532	1,472	1,372
Episodes among members with gestational diabetes diagnoses #1	0	2	1	0	0	0	2	0	9	4	3	5	15
Episodes among members with gestational diabetes diagnoses #2	0	2	1	1	0	0	2	1	10	4	5	5	15
Episodes among members with gestational diabetes diagnoses #3	0	2	3	1	0	1	5	1	11	8	8	7	16
Episodes among members without gestational diabetes diagnosis during pregnancy episode	85	145	202	235	293	272	647	803	1,419	1,643	1,524	1,465	1,356
Combination Products	4	6	9	12	14	6	29	22	47	47	38	33	24
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	1	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	1	1	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	4	6	9	12	14	6	29	21	46	47	38	33	24
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0	5	11	11	19	33	25	18
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	1	0	1	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	2	0	2	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	5	11	9	19	31	25	18
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	1	8	11	12	24	23	45	39	29
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	1	0	0	0	1
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	1	0	0	0	1
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	1	0	0	0	1
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	1	8	11	12	23	23	45	39	28
Insulin	23	25	29	26	33	32	65	65	94	143	119	113	99
Episodes among members with gestational diabetes diagnoses #1	2	2	1	0	1	1	6	3	2	3	3	8	17
Episodes among members with gestational diabetes diagnoses #2	4	2	1	0	1	1	6	3	3	6	4	9	17
Episodes among members with gestational diabetes diagnoses #3	5	2	1	0	1	1	6	3	5	6	5	9	17
Episodes among members without gestational diabetes diagnosis during pregnancy episode	18	23	28	26	32	31	59	62	89	137	114	104	82

Table 6a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Meglitinide Analogs	0	0	0	3	4	0	3	2	2	2	1	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	3	4	0	3	2	2	2	1	0	0
Sulfonylureas	36	51	37	43	49	40	54	59	115	134	110	117	110
Episodes among members with gestational diabetes diagnoses #1	0	0	1	1	0	1	1	3	5	7	14	6	22
Episodes among members with gestational diabetes diagnoses #2	0	0	1	1	0	1	1	3	5	9	15	6	22
Episodes among members with gestational diabetes diagnoses #3	0	0	1	1	0	1	1	3	8	13	16	7	24
Episodes among members without gestational diabetes diagnosis during pregnancy episode	36	51	36	42	49	39	53	56	107	121	94	110	86
Thiazolidinediones	3	15	20	27	37	20	23	24	45	38	24	13	11
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	3	15	20	27	37	20	23	24	45	38	24	13	11

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 6b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Pregnant Cohort with Diabetes													
No use of any ADA at any time during pregnancy	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Biguanide	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Combination Products	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Insulin	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Meglitinide Analogs	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Sulfonylureas	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Thiazolidinediones	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Non-Pregnant Cohort[1,2] with Diabetes													
No use of any ADA at any time during pregnancy	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Biguanide	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Combination Products	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Insulin	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Meglitinide Analogs	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Sulfonylureas	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Thiazolidinediones	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 6c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Pregnant Cohort with Lupus													
No use of any ADA at any time during pregnancy	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	3	1	2	1	1	1	6	4	5	14	8	9	16
Episodes among members with gestational diabetes diagnoses #1	3	1	2	1	1	1	5	3	5	11	6	7	15
Episodes among members with gestational diabetes diagnoses #2	3	1	2	1	1	1	5	4	5	13	6	8	16
Episodes among members with gestational diabetes diagnoses #3	3	1	2	1	1	1	5	4	5	13	6	8	16
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	1	0	0	1	2	1	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Biguanide	1	0	0	0	0	0	1	0	0	2	3	0	1
Episodes among members with gestational diabetes diagnoses #1	1	0	0	0	0	0	0	0	0	1	2	0	1
Episodes among members with gestational diabetes diagnoses #2	1	0	0	0	0	0	0	0	0	1	2	0	1
Episodes among members with gestational diabetes diagnoses #3	1	0	0	0	0	0	0	0	0	1	2	0	1
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	1	0	0	1	1	0	0
Combination Products	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Insulin	2	1	1	1	1	1	3	4	3	5	2	6	8
Episodes among members with gestational diabetes diagnoses #1	2	1	1	1	1	1	3	3	3	4	2	5	7
Episodes among members with gestational diabetes diagnoses #2	2	1	1	1	1	1	3	4	3	5	2	5	8
Episodes among members with gestational diabetes diagnoses #3	2	1	1	1	1	1	3	4	3	5	2	5	8
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	1	0

Table 6c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Meglitinide Analogs	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Sulfonylureas	0	0	1	0	1	0	2	1	2	8	4	3	10
Episodes among members with gestational diabetes diagnoses #1	0	0	1	0	1	0	2	1	2	7	3	2	10
Episodes among members with gestational diabetes diagnoses #2	0	0	1	0	1	0	2	1	2	8	3	3	10
Episodes among members with gestational diabetes diagnoses #3	0	0	1	0	1	0	2	1	2	8	3	3	10
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	1	0	0
Thiazolidinediones	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Non-Pregnant Cohort[1,2] with Lupus													
No use of any ADA at any time during pregnancy	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	0	0	0	0	0	0	1	2	1	1	4	2
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	1	2	1	1	4	2
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Biguanide	0	0	0	0	0	0	0	0	2	1	1	4	2
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	2	1	1	4	2
Combination Products	0	0	0	0	0	0	0	1	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	1	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Insulin	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Meglitinide Analogs	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Sulfonylureas	0	0	0	0	0	0	0	0	0	0	0	1	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	1	0
Thiazolidinediones	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 6d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Pregnant Cohort with MS													
No use of any ADA at any time during pregnancy	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	0	0	0	0	0	4	3	3	12	13	13	10
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	3	3	3	11	12	11	8
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	3	3	3	11	13	13	9
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	3	3	3	11	13	13	9
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	1	0	0	1	0	0	1
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Biguanide	0	0	0	0	0	0	1	0	0	2	0	1	2
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	1	0	1	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	1	0	1	1
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	1	0	1	1
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	1	0	0	1	0	0	1
Combination Products	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Insulin	0	0	0	0	0	0	1	1	2	3	5	4	3
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	1	1	2	3	5	4	3
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	1	1	2	3	5	4	3
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	1	1	2	3	5	4	3
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Meglitinide Analogs	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Sulfonylureas	0	0	0	0	0	0	2	2	1	8	8	8	6
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	2	2	1	8	7	6	5
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	2	2	1	8	8	8	6
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	2	2	1	8	8	8	6
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Thiazolidinediones	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Non-Pregnant Cohort[1,2] with MS													
No use of any ADA at any time during pregnancy	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Antidiabetic Medications – Use of Any Agent	0	0	0	0	1	1	1	0	3	4	1	3	1
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	1	1	1	0	3	4	1	3	1
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Amylin Analog	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0

Table 6d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Biguanide	0	0	0	0	1	1	1	0	2	4	1	1	1
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	1	1	1	0	2	4	1	1	1
Combination Products	0	0	0	0	0	0	0	1	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	1	0	0	0	0	0
Dipeptidyl Peptidase-4 Inhibitors	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Glucagon-like Peptide-1 Receptor Agonists	0	0	0	0	0	0	0	0	0	0	0	1	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	1	0
Insulin	0	0	0	0	0	0	0	0	0	0	0	1	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	1	0

Table 6d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Calendar Year

	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
Meglitinide Analogs	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	0	0	0	0	0
Sulfonylureas	0	0	0	0	0	0	0	0	1	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0	0	1	0	0	0	0
Thiazolidinediones	0	0	0	0	0	0	1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	1	0	0	0	0	0	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 7a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Pregnant Cohort							
No use of Any ADA at any time during pregnancy	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Antidiabetic Medications - Use of Any Agent	531	2,750	9,459	16,662	12,840	4,069	363
Episodes among members with gestational diabetes diagnoses #1	406	2,153	7,908	14,425	11,318	3,590	295
Episodes among members with gestational diabetes diagnoses #2	446	2,355	8,435	15,417	12,149	3,893	309
Episodes among members with gestational diabetes diagnoses #3	447	2,368	8,457	15,449	12,178	3,900	310
Episodes among members without gestational diabetes diagnosis during pregnancy episode	84	382	1,002	1,213	662	169	53
Alpha-Glucosidase Inhibitors	4	8	21	44	26	12	0
Episodes among members with gestational diabetes diagnoses #1	2	7	21	42	25	11	0
Episodes among members with gestational diabetes diagnoses #2	2	7	21	43	26	12	0
Episodes among members with gestational diabetes diagnoses #3	2	7	21	43	26	12	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	2	1	0	1	0	0	0
Amylin Analogs	0	1	1	2	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	1	1	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	1	1	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	1	0	0	0

Table 7a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Biguanides	103	510	1,609	2,174	1,274	346	58
Episodes among members with gestational diabetes diagnoses #1	44	220	729	1,104	706	208	15
Episodes among members with gestational diabetes diagnoses #2	58	273	822	1,255	846	263	18
Episodes among members with gestational diabetes diagnoses #3	58	277	825	1,263	850	265	18
Episodes among members without gestational diabetes diagnosis during pregnancy episode	45	233	784	911	424	81	40
Combination Products	4	17	30	39	22	9	3
Episodes among members with gestational diabetes diagnoses #1	2	9	20	21	10	3	0
Episodes among members with gestational diabetes diagnoses #2	2	13	23	26	14	6	0
Episodes among members with gestational diabetes diagnoses #3	2	13	23	26	14	6	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	2	4	7	13	8	3	3
DPP4 Inhibitors	0	1	2	3	5	3	1
Episodes among members with gestational diabetes diagnoses #1	0	0	1	2	0	1	0
Episodes among members with gestational diabetes diagnoses #2	0	0	1	2	3	2	0
Episodes among members with gestational diabetes diagnoses #3	0	0	1	2	3	2	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	1	1	2	1	1
Glucagon Like Peptide 1 Receptor Agonists	1	1	2	4	2	2	1
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	1	2	1	1	0
Episodes among members with gestational diabetes diagnoses #3	0	0	1	2	1	1	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	1	1	1	2	1	1	1

Table 7a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Insulin	266	1,259	4,003	7,353	6,004	1,898	142
Episodes among members with gestational diabetes diagnoses #1	218	985	3,422	6,344	5,193	1,621	125
Episodes among members with gestational diabetes diagnoses #2	245	1,125	3,803	7,060	5,787	1,824	132
Episodes among members with gestational diabetes diagnoses #3	245	1,135	3,820	7,084	5,810	1,830	133
Episodes among members without gestational diabetes diagnosis during pregnancy episode	21	124	183	269	194	68	9
Meglitinide Analogs	0	1	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	0	0	0	0
Sulfonylureas	204	1,223	4,701	8,609	6,763	2,223	191
Episodes among members with gestational diabetes diagnoses #1	178	1,129	4,434	8,174	6,372	2,058	178
Episodes among members with gestational diabetes diagnoses #2	189	1,186	4,606	8,504	6,666	2,183	185
Episodes among members with gestational diabetes diagnoses #3	190	1,187	4,612	8,508	6,674	2,183	185
Episodes among members without gestational diabetes diagnosis during pregnancy episode	14	36	89	101	89	40	6
Thiazolidinediones	3	4	17	16	6	4	3
Episodes among members with gestational diabetes diagnoses #1	0	0	4	4	0	1	0
Episodes among members with gestational diabetes diagnoses #2	1	0	5	8	1	1	0
Episodes among members with gestational diabetes diagnoses #3	1	0	5	8	1	1	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	2	4	12	8	5	3	3

Table 7a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Non-Pregnant Cohort[1,2]							
No use of Any ADA at any time during pregnancy	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Antidiabetic Medications - Use of Any Agent	380	1,128	3,062	4,263	2,261	453	63
Episodes among members with gestational diabetes diagnoses #1	0	3	35	61	36	2	0
Episodes among members with gestational diabetes diagnoses #2	0	4	40	67	37	2	0
Episodes among members with gestational diabetes diagnoses #3	0	5	47	80	46	4	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	380	1,123	3,015	4,183	2,215	449	63
Alpha-Glucosidase Inhibitors	1	3	7	17	8	2	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	1	3	7	17	8	2	0
Amylin Analogs	0	0	2	6	1	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	2	6	1	0	0

Table 7a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Biguanides	342	973	2,756	3,766	1,901	360	54
Episodes among members with gestational diabetes diagnoses #1	0	2	14	15	9	1	0
Episodes among members with gestational diabetes diagnoses #2	0	2	16	17	10	1	0
Episodes among members with gestational diabetes diagnoses #3	0	3	19	23	15	3	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	342	970	2,737	3,743	1,886	357	54
Combination Products	6	33	44	111	78	18	1
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	1	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	1	1	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	6	33	44	110	77	18	1
DPP4 Inhibitors	1	5	17	45	43	10	1
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	1	1	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	2	2	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	1	5	17	43	41	10	1
Glucagon Like Peptide 1 Receptor Agonists	2	12	37	76	52	10	3
Episodes among members with gestational diabetes diagnoses #1	0	0	1	1	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	1	1	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	1	1	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	2	12	36	75	52	10	3
Insulin	43	114	202	279	185	37	6
Episodes among members with gestational diabetes diagnoses #1	0	1	10	23	15	0	0
Episodes among members with gestational diabetes diagnoses #2	0	2	14	26	15	0	0
Episodes among members with gestational diabetes diagnoses #3	0	2	15	29	15	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	43	112	187	250	170	37	6

Table 7a. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Meglitinide Analogs	3	0	6	3	5	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	3	0	6	3	5	0	0
Sulfonylureas	9	56	165	359	276	81	9
Episodes among members with gestational diabetes diagnoses #1	0	1	13	31	15	1	0
Episodes among members with gestational diabetes diagnoses #2	0	1	14	33	15	1	0
Episodes among members with gestational diabetes diagnoses #3	0	1	17	39	17	1	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	9	55	148	320	259	80	9
Thiazolidinediones	12	57	61	83	66	19	2
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	12	57	61	83	66	19	2

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 7b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Pregnant Cohort with Diabetes							
No use of Any ADA at any time during pregnancy	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Antidiabetic Medications - Use of Any Agent	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Amylin Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Biguanides	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Combination Products	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
DPP4 Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Glucagon Like Peptide 1 Receptor Agonists	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Insulin	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Meglitinide Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Sulfonylureas	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Thiazolidinediones	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Non-Pregnant Cohort[1,2] with Diabetes							
No use of Any ADA at any time during pregnancy	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Antidiabetic Medications - Use of Any Agent	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Amylin Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Biguanides	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Combination Products	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
DPP4 Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Glucagon Like Peptide 1 Receptor Agonists	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Insulin	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7b. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Diabetes without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Meglitinide Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Sulfonylureas	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Thiazolidinediones	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 7c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Pregnant Cohort with Lupus							
No use of Any ADA at any time during pregnancy	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Antidiabetic Medications - Use of Any Agent	1	2	16	24	23	5	0
Episodes among members with gestational diabetes diagnoses #1	1	2	13	20	21	4	0
Episodes among members with gestational diabetes diagnoses #2	1	2	14	22	22	5	0
Episodes among members with gestational diabetes diagnoses #3	1	2	14	22	22	5	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	2	2	1	0	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Amylin Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Biguanides	0	0	2	1	4	1	0
Episodes among members with gestational diabetes diagnoses #1	0	0	1	0	3	1	0
Episodes among members with gestational diabetes diagnoses #2	0	0	1	0	3	1	0
Episodes among members with gestational diabetes diagnoses #3	0	0	1	0	3	1	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	1	1	1	0	0

Table 7c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Combination Products	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
DPP4 Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Glucagon Like Peptide 1 Receptor Agonists	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Insulin	1	1	11	9	15	1	0
Episodes among members with gestational diabetes diagnoses #1	1	1	0	8	14	1	0
Episodes among members with gestational diabetes diagnoses #2	1	1	10	9	15	1	0
Episodes among members with gestational diabetes diagnoses #3	1	1	10	9	15	1	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	1	0	0	0	0
Meglitinide Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Sulfonylureas	0	1	4	15	9	3	0
Episodes among members with gestational diabetes diagnoses #1	0	1	4	13	9	2	0
Episodes among members with gestational diabetes diagnoses #2	0	1	4	14	9	3	0
Episodes among members with gestational diabetes diagnoses #3	0	1	4	14	9	3	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	1	0	0	0
Thiazolidinediones	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Non-Pregnant Cohort[1,2] with Lupus							
No use of Any ADA at any time during pregnancy	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Antidiabetic Medications - Use of Any Agent	0	1	0	6	3	0	1
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	6	3	0	1
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Amylin Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Biguanides	0	1	0	5	3	0	1
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	5	3	0	1
Combination Products	0	0	0	1	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	1	0	0	0
DPP4 Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Glucagon Like Peptide 1 Receptor Agonists	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Insulin	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7c. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Lupus without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Meglitinide Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Sulfonylureas	0	0	0	1	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	1	0	0	0
Thiazolidinediones	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 7d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Pregnant Cohort with MS							
No use of Any ADA at any time during pregnancy	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Antidiabetic Medications - Use of Any Agent	0	1	3	26	22	6	0
Episodes among members with gestational diabetes diagnoses #1	0	0	3	23	19	6	0
Episodes among members with gestational diabetes diagnoses #2	0	0	3	24	22	6	0
Episodes among members with gestational diabetes diagnoses #3	0	0	3	24	22	6	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	2	0	0	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Amylin Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Biguanides	0	1	0	4	1	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	2	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	2	1	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	2	1	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	1	0	2	0	0	0

Table 7d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Combination Products	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
DPP4 Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Glucagon Like Peptide 1 Receptor Agonists	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Insulin	0	0	0	8	8	3	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	8	8	3	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	8	8	3	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	8	8	3	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Meglitinide Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Sulfonylureas	0	0	3	15	14	3	0
Episodes among members with gestational diabetes diagnoses #1	0	0	3	14	11	3	0
Episodes among members with gestational diabetes diagnoses #2	0	0	3	15	14	3	0
Episodes among members with gestational diabetes diagnoses #3	0	0	3	15	14	3	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Thiazolidinediones	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Non-Pregnant Cohort[1,2] with MS							
No use of Any ADA at any time during pregnancy	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Antidiabetic Medications - Use of Any Agent	1	1	1	5	6	1	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	1	1	1	5	6	1	0
Alpha-Glucosidase Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Amylin Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0

Table 7d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Biguanides	1	1	0	5	4	1	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	1	1	0	5	4	1	0
Combination Products	0	0	0	1	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	1	0	0	0
DPP4 Inhibitors	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Glucagon Like Peptide 1 Receptor Agonists	0	0	0	0	1	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	1	0	0
Insulin	0	0	1	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	1	0	0	0	0

Table 7d. Prevalence of Medication Use of Pregnant Cohort and Non-Pregnant Cohort[1,2] Members with Pre-Existing Condition of Multiple Sclerosis (MS) without Any Antidiabetic Agent (ADA) Dispensing Prior to Pregnancy by Age Group in Years

	< 20	20-24	25-29	30-34	35-39	40-44	45-54
Meglitinide Analogs	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	0	0	0
Sulfonylureas	0	0	0	0	1	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	0	0	0	0	1	0	0
Thiazolidinediones	1	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #1	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #2	0	0	0	0	0	0	0
Episodes among members with gestational diabetes diagnoses #3	0	0	0	0	0	0	0
Episodes among members without gestational diabetes diagnosis during pregnancy episode	1	0	0	0	0	0	0

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Table 8. Number of Eligible Pregnancy Episodes by Specific Enrollment Criteria

Enrollment Criteria	Episodes
Total unique women with a pregnancy episode, No enrollment criteria	3,082,108
Total unique pregnancy episodes, no enrollment criteria	3,730,489
Medical and drug coverage for at least 330 days prior to the admit date for delivery	2,325,149
Medical and drug coverage for at least 390 days prior to the admit date for delivery	2,143,057
Medical and drug coverage for at least 420 days prior to the admit date for delivery	2,057,568
Medical and drug coverage for at least 480 days prior to the admit date for delivery	1,895,604

Table 9. Metformin Dispensings But No Other Antidiabetic Agent (ADA) Among the Pregnant Cohort and Non-Pregnant Cohort[1,2] in the 183 Days Prior to Pregnancy

Cohort Group	Characteristic	Number
Pregnant Cohort		
A	Total unique women with a pregnancy episode	1,598,705
B	Total unique pregnancy episodes	1,895,604
C	Pregnancy episodes with prior metformin use	34,875
D	Pregnancy episodes with prior metformin use, but no other ADA in 183 days prior to pregnancy	31,302
E	From cohort (D), pregnancy episodes with prior diabetes diagnosis 250.X	3,474
F	From cohort (D), pregnancy episodes without diabetes diagnosis 250.X	27,828
G	From cohort (F), pregnancy episodes with PCOD 256.4 in 183 days prior to pregnancy	13,438
H	From cohort (F), pregnancy episodes with infertility 628 in 183 days prior to pregnancy	11,315
I	From cohort (F), pregnancy episodes with both PCOD and infertility (256.4 OR 638) in 183 days prior to pregnancy	18,296
Non-Pregnant Cohort[1,2]		
A	Total unique women with a non-pregnant episode	1,582,856
B	Total unique non-pregnant episodes	1,895,604
C	Non-pregnant episodes with prior metformin use	26,077
D	Non-pregnant episodes with prior metformin use, but no other ADA in 183 days prior to the non-pregnant episode	19,951
E	From cohort (D), non-pregnant episodes with prior diabetes diagnosis 250.X	5,272
F	From cohort (D), non-pregnant episodes without diabetes diagnosis 250.X	14,679
G	From cohort (F), non-pregnant episodes with PCOD 256.4 in 183 days prior to the non-pregnant episode	5,693
H	From cohort (F), non-pregnant episodes with infertility 628 in 183 days prior to the non-pregnant episode	1,582
I	From cohort (F), non-pregnant episodes with both PCOD and infertility (256.4 OR 638) in 183 days prior to the non-pregnant episode	6,342

[1]Medication use during pregnancy for the non-pregnant cohort is defined as the time corresponding to medication use during pregnancy of the pregnant cohort.

[2]Women in non-pregnant cohort may be pregnant at some point during the request period. Women were eligible for the non-pregnant cohort if they had no evidence of a live-born delivery during the time period of their matched comparator's pregnancy.

Data Partner ID	Start Date[1]	End Date[1]
DP01	1/1/2008	12/31/2013
DP02	1/1/2006	12/31/2013
DP03	1/1/2004	12/31/2013
DP04	1/1/2001	4/30/2012
DP05	1/1/2001	12/31/2013
DP06	1/1/2001	12/31/2013
DP07	1/1/2001	12/31/2013
DP08	1/1/2001	6/30/2012
DP09	6/1/2007	12/31/2013
DP10	1/1/2001	12/31/2013
DP11	1/1/2001	12/31/2013
DP12	1/1/2005	12/31/2013
DP13	1/1/2001	12/31/2013
DP14	1/1/2001	12/31/2013
DP15	1/1/2008	12/31/2013
DP16	1/1/2001	12/31/2012

[1]The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month.

Appendix B. List of Generic Drug Names Used to Define Exposures in this Request

Generic Name

Alpha-Glucosidase Inhibitors
Acarbose
Miglitol

Amylin Analog
Pramlintide

Biguanide
Metformin

Dipeptidyl Peptidase-4 Inhibitors
Alogliptin
Linagliptin
Saxagliptin
Sitagliptin

Glucagon-like Peptide-1 Receptor Agonists
Exenatide
Liraglutide

Meglitinide Analogs
Nateglinide
Repaglinide

Sulfonylureas
Acetohexamide
Chlorpropamide
Glimepiride
Glipizide
Glyburide
Tolazamide
Tolbutamide

Thiazolidinediones
Pioglitazone
Rosiglitazone

Combination Products
Alogliptin combination products
Glipizide combination products
Glyburide combination products
Linagliptin combination products
Pioglitazone combination products
Repaglinide combination products
Rosiglitazone combination products
Saxagliptin combination products
Sitagliptin combination products

Injectable Insulin Product
Insulin

Appendix C. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes Used to Define Gestational Age* in this Request

Code	Code Type	Definition	Algorithm-derived gestational age	
			Weeks	**Days**
		Preterm Birth Codes		
765.21	ICD-9-CM	Less than 24 completed weeks of gestation	24	168
765.22	ICD-9-CM	24 completed weeks of gestation		
765.23	ICD-9-CM	25-26 completed weeks of gestation	26	182
765.24	ICD-9-CM	27-28 completed weeks of gestation	28	196
765.0-765.09	ICD-9-CM	Extreme immaturity		
765.25	ICD-9-CM	29-30 completed weeks of gestation	30	210
765.26	ICD-9-CM	31-32 completed weeks of gestation	32	224
765.27	ICD-9-CM	33-34 completed weeks of gestation	34	238
765.28	ICD-9-CM	35-36 completed weeks of gestation	36	252
765.1-765.19	ICD-9-CM	Other preterm infants		
765.2	ICD-9-CM	Pre-term with unspecified weeks of gestation	35	245
644.21	ICD-9-CM	Onset of delivery before 37 completed weeks of gestation		
		Postterm Birth Codes		
645.1x	ICD-9-CM		41	287
		Post-term pregnancy, delivered, with or without mention of antepartum condition (over 40 weeks to 42 completed weeks gestation)		
766.21	ICD-9-CM	weeks)	41	287
645.2x	ICD-9-CM	Prolonged pregnancy, delivered (pregnancy which has advanced beyond 42 completed weeks gestation)	42	294
766.22	ICD-9-CM	weeks)	42	294

* Gestational age for deliveries without an ICD-9-CM diagnosis code for pre-term or post-term birth in the table is assumed to be 273 days.

Code	Code Type	Care Setting	Description
59409	CPT-4	Inpatient	VAGINAL DELIVERY ONLY
59410	CPT-4	Inpatient	VAGINAL DELIVERY INCL POSTPARTUM CARE
59510	CPT-4	Inpatient	ROUTINE OB CARE INCL ANTEPARTUM CAR, CESAREAN DELIVER, POSTPARTUM CARE
59514	CPT-4	Inpatient	CESAREAN DELIVERY ONLY
59515	CPT-4	Inpatient	CESAREAN DELIVERY, INCL POSTPARTUM CARE
59610	CPT-4	Inpatient	OB CARE INCL ANTEPARTUM CAR, VAG DELIVER, POSTPART CARE. AFTER PREV C-SECT
59612	CPT-4	Inpatient	VAG DELIVERY ONLY AFTER PREV C-SECT
59614	CPT-4	Inpatient	VAG DELIVERY AFTER PREV C-SECT, INCL POSTPARTUM CARE
59618	CPT-4	Inpatient	OB CARE INCL ANTEPARTUM CAR, CES DELIVER, POSTPART CARE. AFTER PREV C-SECT
59620	CPT-4	Inpatient	CESAREAN DELIVERY ONLY AFTER PREV C-SECT
59622	CPT-4	Inpatient	CESAREAN DELIVERY AFTER PREV C-SECT, INCL POSTPARTUM CARE
72	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.0	CPT-4	Inpatient	LOW FORCEPS OPERATION
72.1	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.2	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.21	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.29	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.3	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.31	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.39	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.4	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.5	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.51	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.52	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.53	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.54	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.6	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.7	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.71	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.79	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.8	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
72.9	CPT-4	Inpatient	FORCEPS, VACUUM, AND BREECH DELIVERY
73	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.0	CPT-4	Inpatient	ARTIFICIAL RUPTURE OF MEMBRANES
73.01	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.09	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.1	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.2	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.21	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.22	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.3	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY

Code	Code Type	Care Setting	Description
73.4	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.5	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.51	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.59	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.6	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.8	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.9	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.91	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.92	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.93	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.94	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
73.99	CPT-4	Inpatient	OTHER PROCEDURES INDUCING OR ASSISTING DELIVERY
74.0	CPT-4	Inpatient	Classical Cesarean Section
74.1	CPT-4	Inpatient	CESAREAN SECTION AND REMOVAL OF FETUS
74.2	CPT-4	Inpatient	CESAREAN SECTION AND REMOVAL OF FETUS
74.4	CPT-4	Inpatient	CESAREAN SECTION AND REMOVAL OF FETUS
74.9	CPT-4	Inpatient	CESAREAN SECTION AND REMOVAL OF FETUS
74.99	CPT-4	Inpatient	CESAREAN SECTION AND REMOVAL OF FETUS
641.01	ICD-9-CM	Inpatient	PLACENTA PREVIA WITHOUT HEMORRHAGE, DELIVERED
641.11	ICD-9-CM	Inpatient	HEMORRHAGE FROM PLACENTA PREVIA, DELIVERED
641.21	ICD-9-CM	Inpatient	PREMATURE SEPARATION OF PLACENTA, DELIVERED
641.31	ICD-9-CM	Inpatient	ANTEPARTUM HEMORRHAGE ASSOC WITH COAG DEFECT, DELIVERED
641.81	ICD-9-CM	Inpatient	OTHER ANTEPARTUM HEMORRHAGE, DELIVERED
641.91	ICD-9-CM	Inpatient	UNSPECIFIED ANTEPARTUM HEMORRHAGE, DELIVERED
642.01	ICD-9-CM	Inpatient	BENIGN ESSENTIAL HYPERTENSION WITH DELIVERY
642.02	ICD-9-CM	Inpatient	BENIGN ESSENTIAL HYPERTENSION, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
642.11	ICD-9-CM	Inpatient	HYPERTENSION SECONDARY TO RENAL DISEASE, WITH DELIVERY
642.12	ICD-9-CM	Inpatient	HYPERTENSION SECONDARY TO RENAL DISEASE, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
642.21	ICD-9-CM	Inpatient	OTHER Pre-Existing HYPERTENSION, WITH DELIVERY
642.22	ICD-9-CM	Inpatient	OTHER Pre-Existing HYPERTENSION, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
642.31	ICD-9-CM	Inpatient	TRANSIENT HYPERTENSION OF PREGNANCY, WITH DELIVERY
642.32	ICD-9-CM	Inpatient	TRANSIENT HYPERTENSION OF PREGNANCY, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
642.41	ICD-9-CM	Inpatient	MILD OR UNSPECIFIED PRE-ECLAMPSIA, WITH DELIVERY
642.42	ICD-9-CM	Inpatient	MILD OR UNSPECIFIED PRE-ECLAMPSIA, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
642.51	ICD-9-CM	Inpatient	SEVERE PRE-ECLAMPSIA, WITH DELIVERY
642.52	ICD-9-CM	Inpatient	SEVERE PRE-ECLAMPSIA, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
642.61	ICD-9-CM	Inpatient	ECLAMPSIA, WITH DELIVERY

Code	Code Type	Care Setting	Description
642.62	ICD-9-CM	Inpatient	ECLAMPSIA, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
642.71	ICD-9-CM	Inpatient	Pre-eclampsia or eclampsia superimposed on Pre-Existing hypertension, with delivery
642.72	ICD-9-CM	Inpatient	Pre-eclampsia or eclampsia superimposed on Pre-Existing hypertension, with delivery, with mention postpartum complication
642.91	ICD-9-CM	Inpatient	UNSPECIFIED HYPERTENSION, WITH DELIVERY
642.92	ICD-9-CM	Inpatient	UNSPECIFIED HYPERTENSION, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
643.01	ICD-9-CM	Inpatient	Mild hyperemesis gravidarum, delivered
643.11	ICD-9-CM	Inpatient	Hyperemesis gravidarum with metabolic disturbance, delivered
643.21	ICD-9-CM	Inpatient	LATE VOMITING OF PREGNANCY, DELIVERED
643.81	ICD-9-CM	Inpatient	OTHER VOMITING COMPLICATING PREGNANCY, DELIVERED
643.91	ICD-9-CM	Inpatient	UNSPECIFIED VOMITING OF PREGNANCY, DELIVERED
644.21	ICD-9-CM	Inpatient	EARLY ONSET OF DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
645.01	ICD-9-CM	Inpatient	PROLONGED PREGNANCY, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
645.11	ICD-9-CM	Inpatient	POST TERM PREGNANCY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM CONDO
645.21	ICD-9-CM	Inpatient	PROLONGED PREGNANCY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
645.22	ICD-9-CM	Inpatient	PROLONGED PREGNANCY, DELIVERED, WITH MENT POSTPARTUM COMP
646.01	ICD-9-CM	Inpatient	PAPYRACEOUS FETUS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
646.11	ICD-9-CM	Inpatient	EDEMA OR EXCESSIVE WEIGHT GAIN IN PREGNANCY, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPART CON
646.12	ICD-9-CM	Inpatient	EDEMA OR EXCESSIVE WEIGHT GAIN IN PREGNANCY, WITH DELIVERY, WITH MENT POSTPARTUM COMP
646.21	ICD-9-CM	Inpatient	UNSPECIFIED RENAL DISEASE IN PREGNANCY, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
646.22	ICD-9-CM	Inpatient	UNSPECIFIED RENAL DISEASE IN PREGNANCY, WITH DELIVERY, WITH MENT POSTPARTUM COMP
646.31	ICD-9-CM	Inpatient	HABITUAL ABORTER, DELIVERED, WITH OR WITHOUT MENTION OF ANTEPARTUM COND
646.41	ICD-9-CM	Inpatient	PERIPHERAL NEURITIS IN PREGNANCY, WITH DELIVERY WITH OR WITHOUT MENT ANTEPARTUM COND
646.42	ICD-9-CM	Inpatient	PERIPHERAL NEURITIS IN PREGNANCY, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
646.51	ICD-9-CM	Inpatient	ASYMPTOMATIC BACTERIURIA IN PREGNANCY, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
646.52	ICD-9-CM	Inpatient	ASYMPTOMATIC BACTERIURIA IN PREGNANCY, WITH DELIVERY, WITH MENT POSTPARTUM COMP
646.61	ICD-9-CM	Inpatient	INFECTIONS OF GENITOURINARY TRACT IN PREGNANCY, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
646.62	ICD-9-CM	Inpatient	INFECTIONS OF GENITOURINARY TRACT IN PREGNANCY, WITH DELIVERY, WITH MENT POSTPARTUM COMP

Code	Code Type	Care Setting	Description
646.71	ICD-9-CM	Inpatient	LIVER DISORDERS IN PREGNANCY, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
646.81	ICD-9-CM	Inpatient	OTHER SPECIFIED COMPLICATIONS OF PREGNANCY, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
646.82	ICD-9-CM	Inpatient	OTHER SPECIFIED COMPLICATIONS OF PREGNANCY, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
646.91	ICD-9-CM	Inpatient	UNSPECIFIED COMPLICATION OF PREGNANCY, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
647.01	ICD-9-CM	Inpatient	SYPHILIS OF MOTHER, COMPLICATING PREGNANCY, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
647.02	ICD-9-CM	Inpatient	SYPHILIS OF MOTHER, COMPLICATING PREGNANCY, WITH DELIVERY, WITH MENT POSTPARTUM COMP
647.11	ICD-9-CM	Inpatient	GONORRHEA OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
647.12	ICD-9-CM	Inpatient	GONORRHEA OF MOTHER, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
647.21	ICD-9-CM	Inpatient	OTHER VENEREAL DISEASES OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
647.22	ICD-9-CM	Inpatient	OTHER VENEREAL DISEASES OF MOTHER, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
647.31	ICD-9-CM	Inpatient	TUBERCULOSIS OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
647.32	ICD-9-CM	Inpatient	TUBERCULOSIS OF MOTHER, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
647.41	ICD-9-CM	Inpatient	MALARIA OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
647.42	ICD-9-CM	Inpatient	MALARIA OF MOTHER, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
647.51	ICD-9-CM	Inpatient	RUBELLA OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
647.52	ICD-9-CM	Inpatient	RUBELLA OF MOTHER, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
647.61	ICD-9-CM	Inpatient	OTHER VIRAL DISEASES OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
647.62	ICD-9-CM	Inpatient	OTHER VIRAL DISEASES OF MOTHER, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
647.81	ICD-9-CM	Inpatient	OTHER SPECIFIED INFECTIOUS AND PARASITIC DISEASES OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
647.82	ICD-9-CM	Inpatient	OTHER SPECIFIED INFECTIOUS AND PARASITIC DISEASES OF MOTHER, WITH DELIVERY, WITH MENTION POSTPARTUM COND
647.91	ICD-9-CM	Inpatient	UNSPECIFIED INFECTION OR INFESTATION OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
647.92	ICD-9-CM	Inpatient	UNSPECIFIED INFECTION OR INFESTATION OF MOTHER, WITH DELIVERY, WITH MENTION POSTPARTUM COND
648.01	ICD-9-CM	Inpatient	DIABETES MELLITUS OF MOTHER, WITH DELIVERY
648.02	ICD-9-CM	Inpatient	DIABETES MELLITUS OF MOTHER, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
648.11	ICD-9-CM	Inpatient	THYROID DYSFUNCTION OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes and Current Procedural Terminology, 4th Edition (CPT-4) Procedure Codes Used to Define Live Birth Deliveries in this Request

Code	Code Type	Care Setting	Description
648.12	ICD-9-CM	Inpatient	THYROID DYSFUNCTION OF MOTHER, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
648.21	ICD-9-CM	Inpatient	ANEMIA OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
648.22	ICD-9-CM	Inpatient	ANEMIA OF MOTHER, WITH DELIVERY, WITH MENTION OF POSTPART COMP
648.31	ICD-9-CM	Inpatient	DRUG DEPENDENCE OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
648.32	ICD-9-CM	Inpatient	DRUG DEPENDENCE OF MOTHER, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
648.41	ICD-9-CM	Inpatient	MENTAL DISORDERS OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
648.42	ICD-9-CM	Inpatient	MENTAL DISORDERS OF MOTHER, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
648.51	ICD-9-CM	Inpatient	CONGENITAL CARDIOVASCULAR DISORDERS OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
648.52	ICD-9-CM	Inpatient	CONGENITAL CARDIOVASCULAR DISORDERS OF MOTHER, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
648.61	ICD-9-CM	Inpatient	OTHER CARDIOVASCULAR DISEASES OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
648.62	ICD-9-CM	Inpatient	OTHER CARDIOVASCULAR DISEASES OF MOTHER, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
648.71	ICD-9-CM	Inpatient	BONE AND JOINT DISORDERS OF BACK, PELVIS, AND LOWER LIMBS, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
648.72	ICD-9-CM	Inpatient	BONE AND JOINT DISORDERS OF BACK, PELVIS, AND LOWER LIMBS, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
648.81	ICD-9-CM	Inpatient	ABNORMAL GLUCOSE TOLERANCE OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
648.82	ICD-9-CM	Inpatient	ABNORMAL GLUCOSE TOLERANCE OF MOTHER, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
648.91	ICD-9-CM	Inpatient	OTHER CURRENT CONDITIONS CLASSIFIABLE ELSEWHERE OF MOTHER, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
648.92	ICD-9-CM	Inpatient	OTHER CURRENT CONDITIONS CLASSIFIABLE ELSEWHERE OF MOTHER, WITH MENTION POSTPARTUM COMP
649.01	ICD-9-CM	Inpatient	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition
649.02	ICD-9-CM	Inpatient	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication
649.11	ICD-9-CM	Inpatient	Obesity complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition
649.12	ICD-9-CM	Inpatient	Obesity complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication
649.21	ICD-9-CM	Inpatient	Bariatric surgery status complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition

Code	Code Type	Care Setting	Description
649.22	ICD-9-CM	Inpatient	Bariatric surgery status complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication
649.31	ICD-9-CM	Inpatient	Coagulation defects complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition
649.32	ICD-9-CM	Inpatient	Coagulation defects complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication
649.41	ICD-9-CM	Inpatient	Epilepsy complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition
649.42	ICD-9-CM	Inpatient	Epilepsy complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication
649.51	ICD-9-CM	Inpatient	Spotting complicating pregnancy, delivered, with or without mention of antepartum condition
649.61	ICD-9-CM	Inpatient	Uterine size date discrepancy, delivered, with or without mention of antepartum condition
649.62	ICD-9-CM	Inpatient	Uterine size date discrepancy, delivered, with mention of postpartum complication
649.71	ICD-9-CM	Inpatient	Cervical shortening, delivered, with or without mention of antepartum condition
649.81	ICD-9-CM	Inpatient	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39 completed weeks gestation, with delivery by (planned) cesarean section, delivered, with or without mention of antepartum condition
649.82	ICD-9-CM	Inpatient	Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39 completed weeks gestation, with delivery by (planned) cesarean section, delivered, with mention of postpartum complication
650	ICD-9-CM	Inpatient	NORMAL DELIVERY
651.01	ICD-9-CM	Inpatient	TWIN PREGNANCY, DELIVERED WITH OR WITHOUT MENTION ANTEPARTUM COND
651.11	ICD-9-CM	Inpatient	TRIPLET PREGNANCY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
651.21	ICD-9-CM	Inpatient	QUADRUPLET PREGNANCY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
651.31	ICD-9-CM	Inpatient	TWIN PREGNANCY WITH FETAL LOSS AND RETENTION OF ONE FETUS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
651.41	ICD-9-CM	Inpatient	TRIPLET PREGNANCY WITH FETAL LOSS AND RETENTION OF ONE OR MORE FETUS(ES), DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
651.51	ICD-9-CM	Inpatient	QUADRUPLET PREGNANCY WITH FETAL LOSS AND RETENTION OF ONE OR MORE FETUS(ES), DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
651.61	ICD-9-CM	Inpatient	OTHER MULTIPLE PREGNANCY WITH FETAL LOSS AND RETENTION OF ONE OR MORE FETUS(ES), DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
651.71	ICD-9-CM	Inpatient	Multiple gestation following (elective) fetal reduction, delivered, with or without mention of antepartum condition
651.81	ICD-9-CM	Inpatient	OTHER SPECIFIED MULTIPLE GESTATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
651.91	ICD-9-CM	Inpatient	UNSPECIFIED MULTIPLE GESTATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
652.01	ICD-9-CM	Inpatient	UNSTABLE LIE, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND

Code	Code Type	Care Setting	Description
652.11	ICD-9-CM	Inpatient	BREECH OR OTHER MALPRESENTATION SUCCESSFULLY CONVERTED TO CEPHALIC PRESENTATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
652.21	ICD-9-CM	Inpatient	BREECH PRESENTATION WITHOUT MENTION OF VERSION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
652.31	ICD-9-CM	Inpatient	TRANSVERSE OR OBLIQUE PRESENTATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
652.41	ICD-9-CM	Inpatient	FACE OR BROW PRESENTATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
652.51	ICD-9-CM	Inpatient	HIGH HEAD AT TERM, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
652.61	ICD-9-CM	Inpatient	MULTIPLE GESTATION WITH MALPRESENTATION OF ONE FETUS OR MORE, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
652.71	ICD-9-CM	Inpatient	PROLAPSED ARM OF FETUS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
652.81	ICD-9-CM	Inpatient	OTHER SPECIFIED MALPOSITION OR MALPRESENTATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
652.91	ICD-9-CM	Inpatient	UNSPECIFIED MALPOSITION OR MALPRESENTATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
653.01	ICD-9-CM	Inpatient	MAJOR ABNORMALITY OF BONY PELVIS, NOT FURTHER SPECIFIED, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
653.11	ICD-9-CM	Inpatient	GENERALLY CONTRACTED PELVIS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
653.21	ICD-9-CM	Inpatient	INLET CONTRACTION OF PELVIS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
653.31	ICD-9-CM	Inpatient	OUTLET CONTRACTION OF PELVIS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
653.41	ICD-9-CM	Inpatient	FETOPELVIC DISPROPORTION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
653.51	ICD-9-CM	Inpatient	UNUSUALLY LARGE FETUS CAUSING DISPROPORTION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
653.61	ICD-9-CM	Inpatient	HYDROCEPHALIC FETUS CAUSING DISPROPORTION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
653.71	ICD-9-CM	Inpatient	OTHER FETAL ABNORMALITY CAUSING DISPROPORTION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
653.81	ICD-9-CM	Inpatient	DISPROPORTION OF OTHER ORIGIN, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
653.91	ICD-9-CM	Inpatient	UNSPECIFIED DISPROPORTION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
654.01	ICD-9-CM	Inpatient	CONGENITAL ABNORMALITIES OF UTERUS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
654.02	ICD-9-CM	Inpatient	CONGENITAL ABNORMALITIES OF UTERUS, DELIVERED, WITH MENTION POSTPARTUM COMP
654.11	ICD-9-CM	Inpatient	TUMORS OF BODY OF UTERUS, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND

Code	Code Type	Care Setting	Description
654.12	ICD-9-CM	Inpatient	TUMORS OF BODY OF UTERUS, DELIVERED, WITH MENTION OF POSTPARTUM COMP
654.21	ICD-9-CM	Inpatient	PREVIOUS CESAREAN DELIVERY, DELIVERED, WITH OR WITHOUT MENT ANTEPARTUM COND
654.31	ICD-9-CM	Inpatient	RETROVERTED AND INCARCERATED GRAVID UTERUS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
654.32	ICD-9-CM	Inpatient	RETROVERTED AND INCARCERATED GRAVID UTERUS, DELIVERED, WITH MENT POSTPARTUM COMP
654.41	ICD-9-CM	Inpatient	OTHER ABNORMALITIES IN SHAPE OR POSITION OF GRAVID UTERUS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
654.42	ICD-9-CM	Inpatient	OTHER ABNORMALITIES IN SHAPE OR POSITION OF GRAVID UTERUS, DELIVERED WITH MENTION POSTPARTUM COMP
654.51	ICD-9-CM	Inpatient	CERVICAL INCOMPETENCE, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
654.52	ICD-9-CM	Inpatient	CERVICAL INCOMPETENCE, DELIVERED, WITH MENTION OF POSTPARTUM COMP
654.61	ICD-9-CM	Inpatient	OTHER CONGENITAL OR ACQUIRED ABNORMALITY OF CERVIX, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
654.62	ICD-9-CM	Inpatient	OTHER CONGENITAL OR ACQUIRED ABNORMALITY OF CERVIX, DELIVERY, WITH MENTION POSTPARTUM COMP
654.71	ICD-9-CM	Inpatient	CONGENITAL OR ACQUIRED ABNORMALITY OF VAGINA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
654.72	ICD-9-CM	Inpatient	CONGENITAL OR ACQUIRED ABNORMALITY OF VAGINA, DELIVERED, WITH MENTION POSTPARTUM COMP
654.81	ICD-9-CM	Inpatient	CONGENITAL OR ACQUIRED ABNORMALITY OF VULVA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
654.82	ICD-9-CM	Inpatient	CONGENITAL OR ACQUIRED ABNORMALITY OF VULVA, DELIVERED, WITH MENTION POSTPARTUM COMP
654.91	ICD-9-CM	Inpatient	OTHER AND UNSPECIFIED ABNORMALITY OF ORGANS AND SOFT TISSUE, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
654.92	ICD-9-CM	Inpatient	OTHER AND UNSPECIFIED ABNORMALITY OF ORGANS AND SOFT TISSUE, DELIVERED WITH MENTION POSTPARTUM COMP
655.01	ICD-9-CM	Inpatient	CENTRAL NERVOUS SYSTEM MALFORMATION IN FETUS, WITH DELIVERY, , WITH OR WITHOUT MENTION ANTEPARTUM COND
655.11	ICD-9-CM	Inpatient	CHROMOSOMAL ABNORMALITY IN FETUS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
655.21	ICD-9-CM	Inpatient	HEREDITARY DISEASE IN FAMILY POSSIBLY AFFECTING FETUS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
655.31	ICD-9-CM	Inpatient	SUSPECTED DAMAGE TO FETUS FROM VIRAL DISEASE IN THE MOTHER, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
655.41	ICD-9-CM	Inpatient	SUSPECTED DAMAGE TO FETUS FROM OTHER DISEASE IN THE MOTHER, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
655.51	ICD-9-CM	Inpatient	SUSPECTED DAMAGE TO FETUS FROM DRUGS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND

Code	Code Type	Care Setting	Description
655.61	ICD-9-CM	Inpatient	SUSPECTED DAMAGE TO FETUS FROM RADIATION, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
655.71	ICD-9-CM	Inpatient	DECREASED FETAL MOVEMENTS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
655.81	ICD-9-CM	Inpatient	OTHER KNOWN OR SUSPECTED FETAL ABNORMALITY, NOT ELSEWHERE, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
655.91	ICD-9-CM	Inpatient	UNSPECIFIED SUSPECTED FETAL ABNORMALITY, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
656.01	ICD-9-CM	Inpatient	FETAL-MATERNAL HEMORRHAGE, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
656.11	ICD-9-CM	Inpatient	RHESUS ISOIMMUNIZATION, AFFECTING MANAGEMENT OF MOTHER, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
656.21	ICD-9-CM	Inpatient	ISOIMMUNIZATION FROM OTHER AND UNSPECIFIED BLOOD-GROUP, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
656.31	ICD-9-CM	Inpatient	FETAL DISTRESS, AFFECTING MANAGEMENT OF MOTHER, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
656.41	ICD-9-CM	Inpatient	INTRAUTERINE DEATH, AFFECTING MANAGEMENT OF MOTHER, DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
656.51	ICD-9-CM	Inpatient	POOR FETAL GROWTH, AFFECTING MANAGEMENT OF MOTHER, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
656.61	ICD-9-CM	Inpatient	EXCESSIVE FETAL GROWTH, AFFECTING MANAGEMENT OF MOTHER, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
656.71	ICD-9-CM	Inpatient	OTHER PLACENTAL CONDITIONS, AFFECTING MANAGEMENT OF MOTHER, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
656.81	ICD-9-CM	Inpatient	OTHER SPECIFIED FETAL AND PLACENTAL PROBLEMS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
656.91	ICD-9-CM	Inpatient	UNSPECIFIED FETAL AND PLACENTAL PROBLEM, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
657.01	ICD-9-CM	Inpatient	POLYHYDRAMNIOS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
658.01	ICD-9-CM	Inpatient	OLIGOHYDRAMNIOS, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
658.11	ICD-9-CM	Inpatient	PREMATURE RUPTURE OF MEMBRANES, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
658.21	ICD-9-CM	Inpatient	DELAYED DELIVERY AFTER SPONTANEOUS OR UNSPECIFIED RUPTURE, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
658.31	ICD-9-CM	Inpatient	DELAYED DELIVERY AFTER ARTIFICIAL RUPTURE OF MEMBRANES, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
658.41	ICD-9-CM	Inpatient	INFECTION OF AMNIOTIC CAVITY, DELIVERED , WITH OR WITHOUT MENTION ANTEPARTUM COND
658.81	ICD-9-CM	Inpatient	OTHER PROBLEMS ASSOCIATED WITH AMNIOTIC CAVITY AND MEMBRANE, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
658.91	ICD-9-CM	Inpatient	UNSPECIFIED PROBLEM ASSOCIATED WITH AMNIOTIC CAVITY AND MEMBRANE, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes and Current Procedural Terminology, 4th Edition (CPT-4) Procedure Codes Used to Define Live Birth Deliveries in this Request

Code	Code Type	Care Setting	Description
659.01	ICD-9-CM	Inpatient	FAILED MECHANICAL INDUCTION OF LABOR, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
659.11	ICD-9-CM	Inpatient	FAILED MEDICAL OR UNSPECIFIED INDUCTION OF LABOR, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
659.21	ICD-9-CM	Inpatient	UNSPECIFIED TYPE MATERNAL PYREXIA DURING LABOR, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
659.31	ICD-9-CM	Inpatient	GENERALIZED INFECTION DURING LABOR, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
659.41	ICD-9-CM	Inpatient	GRAND MULTIPARITY, WITH CURRENT PREGNANCY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
659.51	ICD-9-CM	Inpatient	ELDERLY PRIMIGRAVIDA, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
659.61	ICD-9-CM	Inpatient	ELDERLY MULTIGRAVIDA, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
659.71	ICD-9-CM	Inpatient	ABNORMALITY IN FETAL HEART RATE/RHYTHM, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
659.81	ICD-9-CM	Inpatient	OTHER SPECIFIED INDICATIONS FOR CARE OR INTERVENTION RELATED TO LABOR AND DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
659.91	ICD-9-CM	Inpatient	UNSPECIFIED INDICATION FOR CARE OR INTERVENTION RELATED TO LABOR AND DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
660.01	ICD-9-CM	Inpatient	OBSTRUCTION CAUSED BY MALPOSITION OF FETUS AT ONSET OF LABOR, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
660.11	ICD-9-CM	Inpatient	OBSTRUCTION BY BONY PELVIS DURING LABOR, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
660.21	ICD-9-CM	Inpatient	OBSTRUCTION BY ABNORMAL PELVIC SOFT TISSUES DURING LABOR, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
660.31	ICD-9-CM	Inpatient	DEEP TRANSVERSE ARREST AND PERSISTENT OCCIPITOPOSTERIOR POSITION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
660.41	ICD-9-CM	Inpatient	SHOULDER (GIRDLE) DYSTOCIA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
660.51	ICD-9-CM	Inpatient	LOCKED TWINS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
660.61	ICD-9-CM	Inpatient	FAILED TRIAL OF LABOR, UNSPECIFIED, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
660.71	ICD-9-CM	Inpatient	FAILED FORCEPS OR VACUUM EXTRACTOR, UNSPECIFIED, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
660.81	ICD-9-CM	Inpatient	OTHER CAUSES OF OBSTRUCTED LABOR, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
660.91	ICD-9-CM	Inpatient	UNSPECIFIED OBSTRUCTED LABOR, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
661.01	ICD-9-CM	Inpatient	PRIMARY UTERINE INERTIA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
661.11	ICD-9-CM	Inpatient	SECONDARY UTERINE INERTIA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND

Code	Code Type	Care Setting	Description
661.21	ICD-9-CM	Inpatient	OTHER AND UNSPECIFIED UTERINE INERTIA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
661.31	ICD-9-CM	Inpatient	PRECIPITATE LABOR, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
661.41	ICD-9-CM	Inpatient	HYPERTONIC, INCOORDINATE, OR PROLONGED UTERINE CONTRACTIONS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
661.91	ICD-9-CM	Inpatient	UNSPECIFIED ABNORMALITY OF LABOR, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
662.01	ICD-9-CM	Inpatient	PROLONGED FIRST STAGE OF LABOR, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
662.11	ICD-9-CM	Inpatient	PROLONGED LABOR, UNSPECIFIED TYPE, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
662.21	ICD-9-CM	Inpatient	PROLONGED SECOND STAGE OF LABOR, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
662.31	ICD-9-CM	Inpatient	DELAYED DELIVERY OF SECOND TWIN, TRIPLET, ETC., DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
663.01	ICD-9-CM	Inpatient	PROLAPSE OF CORD COMPLICATING LABOR AND DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
663.11	ICD-9-CM	Inpatient	CORD AROUND NECK, WITH COMPRESSION, COMPLICATING LABOR AND DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
663.21	ICD-9-CM	Inpatient	OTHER AND UNSPECIFIED CORD ENTANGLEMENT, WITH COMPRESSION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
663.31	ICD-9-CM	Inpatient	OTHER AND UNSPECIFIED CORD ENTANGLEMENT, WITHOUT MENTION OF COMPRESSION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
663.41	ICD-9-CM	Inpatient	SHORT CORD COMPLICATING LABOR AND DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
663.51	ICD-9-CM	Inpatient	VASA PREVIA COMPLICATING LABOR AND DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
663.61	ICD-9-CM	Inpatient	VASCULAR LESIONS OF CORD COMPLICATING LABOR AND DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
663.81	ICD-9-CM	Inpatient	OTHER UMBILICAL CORD COMPLICATIONS DURING LABOR AND DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
663.91	ICD-9-CM	Inpatient	UNSPECIFIED UMBILICAL CORD COMPLICATION DURING LABOR AND DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
664.01	ICD-9-CM	Inpatient	FIRST-DEGREE PERINEAL LACERATION, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
664.11	ICD-9-CM	Inpatient	SECOND-DEGREE PERINEAL LACERATION, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
664.21	ICD-9-CM	Inpatient	THIRD-DEGREE PERINEAL LACERATION, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
664.31	ICD-9-CM	Inpatient	FOURTH-DEGREE PERINEAL LACERATION, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
664.41	ICD-9-CM	Inpatient	UNSPECIFIED PERINEAL LACERATION, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND

Code	Code Type	Care Setting	Description
664.51	ICD-9-CM	Inpatient	VULVAR AND PERINEAL HEMATOMA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
664.61	ICD-9-CM	Inpatient	Anal sphincter tear complicating delivery, not associated with third-degree perineal laceration, delivered, WITH OR WITHOUT MENTION ANTEPARTUM COND
664.81	ICD-9-CM	Inpatient	OTHER SPECIFIED TRAUMA TO PERINEUM AND VULVA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
664.91	ICD-9-CM	Inpatient	UNSPECIFIED TRAUMA TO PERINEUM AND VULVA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
665.01	ICD-9-CM	Inpatient	RUPTURE OF UTERUS BEFORE ONSET OF LABOR, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
665.11	ICD-9-CM	Inpatient	RUPTURE OF UTERUS DURING LABOR, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
665.22	ICD-9-CM	Inpatient	INVERSION OF UTERUS, DELIVERED WITH POSTPARTUM COMPLICATION
665.31	ICD-9-CM	Inpatient	LACERATION OF CERVIX, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
665.41	ICD-9-CM	Inpatient	HIGH VAGINAL LACERATION, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
665.51	ICD-9-CM	Inpatient	OTHER INJURY TO PELVIC ORGANS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
665.61	ICD-9-CM	Inpatient	DAMAGE TO PELVIC JOINTS AND LIGAMENTS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
665.71	ICD-9-CM	Inpatient	PELVIC HEMATOMA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
665.72	ICD-9-CM	Inpatient	PELVIC HEMATOMA, DELIVERED WITH POSTPARTUM COMPLICATION
665.81	ICD-9-CM	Inpatient	OTHER SPECIFIED OBSTETRICAL TRAUMA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
665.82	ICD-9-CM	Inpatient	OTHER SPECIFIED OBSTETRICAL TRAUMA, DELIVERED, WITH POSTPARTUM COMP
665.91	ICD-9-CM	Inpatient	UNSPECIFIED OBSTETRICAL TRAUMA, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
665.92	ICD-9-CM	Inpatient	UNSPECIFIED OBSTETRICAL TRAUMA, DELIVERED, WITH POSTPARTUM COMP
666.02	ICD-9-CM	Inpatient	THIRD-STAGE POSTPARTUM HEMORRHAGE, WITH DELIVERY, WITH POSTPARTUM COMP
666.12	ICD-9-CM	Inpatient	OTHER IMMEDIATE POSTPARTUM HEMORRHAGE, WITH DELIVERY, WITH MENT POSTPARTUM COMP
666.22	ICD-9-CM	Inpatient	DELAYED AND SECONDARY POSTPARTUM HEMORRHAGE, WITH DELIVERY, WITH MENT POSTPARTUM COMP
666.32	ICD-9-CM	Inpatient	POSTPARTUM COAGULATION DEFECTS, WITH DELIVERY, WITH MENT POSTPARTUM COMP
667.02	ICD-9-CM	Inpatient	RETAINED PLACENTA WITHOUT HEMORRHAGE, WITH DELIVERY, WITH MENT POSTPARTUM COMP
667.12	ICD-9-CM	Inpatient	RETAINED PORTIONS OF PLACENTA OR MEMBRANES, WITHOUT HEMORRHAGE, WITH DELIVERY, WITH MENT POSTPARTUM COMP
668.01	ICD-9-CM	Inpatient	PULMONARY COMPLICATIONS OF ANESTHESIA OR OTHER SEDATION IN LABOR AND DELIVERY, DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND

Code	Code Type	Care Setting	Description
668.02	ICD-9-CM	Inpatient	PULMONARY COMPLICATIONS OF ANESTHESIA OR OTHER SEDATION IN LABOR AND DELIVERY, DELIVERY, WITH MENT POSTPARTUM COMP
668.11	ICD-9-CM	Inpatient	CARDIAC COMPLICATIONS OF ANESTHESIA OR OTHER SEDATION IN LABOR AND DELIVERY, DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
668.12	ICD-9-CM	Inpatient	CARDIAC COMPLICATIONS OF ANESTHESIA OR OTHER SEDATION IN LABOR AND DELIVERY, DELIVERY, WITH MENT POSTPARTUM COMP
668.21	ICD-9-CM	Inpatient	CENTRAL NERVOUS SYSTEM COMPLICATIONS OF ANESTHESIA OR OTHER SEDATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
668.22	ICD-9-CM	Inpatient	CENTRAL NERVOUS SYSTEM COMPLICATIONS OF ANESTHESIA OR OTHER SEDATION, DELIVERED, WITH MENT POSTPARTUM COMP
668.81	ICD-9-CM	Inpatient	OTHER COMPLICATIONS OF ANESTHESIA OR OTHER SEDATION IN LABOR AND DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
668.82	ICD-9-CM	Inpatient	OTHER COMPLICATIONS OF ANESTHESIA OR OTHER SEDATION IN LABOR AND DELIVERY, DELIVERED, WITH MENT POSTPARTUM COMP
668.91	ICD-9-CM	Inpatient	UNSPECIFIED COMPLICATION OF ANESTHESIA OR OTHER SEDATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
668.92	ICD-9-CM	Inpatient	UNSPECIFIED COMPLICATION OF ANESTHESIA OR OTHER SEDATION, DELIVERED, WITH MENT POSTPARTUM COMP
669.01	ICD-9-CM	Inpatient	MATERNAL DISTRESS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
669.02	ICD-9-CM	Inpatient	MATERNAL DISTRESS, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
669.11	ICD-9-CM	Inpatient	SHOCK DURING OR FOLLOWING LABOR AND DELIVERY, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
669.12	ICD-9-CM	Inpatient	SHOCK DURING OR FOLLOWING LABOR AND DELIVERY, WITH DELIVERY, WITH MENT POSTPARTUM COMP
669.21	ICD-9-CM	Inpatient	MATERNAL HYPOTENSION SYNDROME, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
669.22	ICD-9-CM	Inpatient	MATERNAL HYPOTENSION SYNDROME, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
669.32	ICD-9-CM	Inpatient	ACUTE RENAL FAILURE WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
669.41	ICD-9-CM	Inpatient	OTHER COMPLICATIONS OF OBSTETRICAL SURGERY AND PROCEDURES, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
669.42	ICD-9-CM	Inpatient	OTHER COMPLICATIONS OF OBSTETRICAL SURGERY AND PROCEDURES, DELIVERED, WITH MENTION POSTPARTUM COMP
669.51	ICD-9-CM	Inpatient	FORCEPS OR VACUUM EXTRACTOR DELIVERY WITHOUT MENTION OF INDICATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
669.61	ICD-9-CM	Inpatient	BREECH EXTRACTION, WITHOUT MENTION OF INDICATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
669.71	ICD-9-CM	Inpatient	CESAREAN DELIVERY, WITHOUT MENTION OF INDICATION, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND
669.81	ICD-9-CM	Inpatient	OTHER COMPLICATIONS OF LABOR AND DELIVERY, DELIVERED, WITH OR WITHOUT MENTION ANTEPARTUM COND

Code	Code Type	Care Setting	Description
669.82	ICD-9-CM	Inpatient	Other complication of labor and delivery, delivered, with mention of postpartum complication
669.91	ICD-9-CM	Inpatient	UNSPECIFIED COMPLICATION OF LABOR AND DELIVERY, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
669.92	ICD-9-CM	Inpatient	UNSPECIFIED COMPLICATION OF LABOR AND DELIVERY, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
670.02	ICD-9-CM	Inpatient	MAJOR PUERPERAL INFECTION, DELIVERED, WITH MENTION POSTPARTUM COMP
670.12	ICD-9-CM	Inpatient	PUERPERAL ENDOMETRITIS, DELIVERED, WITH MENTION OF POSTPARTUM COMPLICATION
670.22	ICD-9-CM	Inpatient	PUERPERAL SEPSIS, DELIVERED, WITH MENTION OF POSTPARTUM COMPLICATION
670.32	ICD-9-CM	Inpatient	PUERPERAL SEPTIC THROMBOPHLEBITIS, DELIVERED, WITH MENTION OF POSTPARTUM COMPLICATION
670.82	ICD-9-CM	Inpatient	OTHER MAJOR PUERPERAL INFECTION, DELIVERED, WITH MENTION OF POSTPARTUM COMPLICATION
671.01	ICD-9-CM	Inpatient	VARICOSE VEINS OF LEGS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
671.02	ICD-9-CM	Inpatient	VARICOSE VEINS OF LEGS, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
671.11	ICD-9-CM	Inpatient	VARICOSE VEINS OF VULVA AND PERINEUM, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
671.12	ICD-9-CM	Inpatient	VARICOSE VEINS OF VULVA AND PERINEUM, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
671.21	ICD-9-CM	Inpatient	SUPERFICIAL THROMBOPHLEBITIS WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
671.22	ICD-9-CM	Inpatient	SUPERFICIAL THROMBOPHLEBITIS WITH DELIVERY, WITH MENTION POSTPARTUM COMP
671.31	ICD-9-CM	Inpatient	DEEP PHLEBOTHROMBOSIS, ANTEPARTUM, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
671.42	ICD-9-CM	Inpatient	DEEP PHLEBOTHROMBOSIS, POSTPARTUM, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
671.51	ICD-9-CM	Inpatient	OTHER PHLEBITIS AND THROMBOSIS WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
671.52	ICD-9-CM	Inpatient	OTHER PHLEBITIS AND THROMBOSIS WITH DELIVERY, WITH MENTION POSTPARTUM COMP
671.81	ICD-9-CM	Inpatient	OTHER VENOUS COMPLICATIONS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
671.82	ICD-9-CM	Inpatient	OTHER VENOUS COMPLICATIONS, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
671.91	ICD-9-CM	Inpatient	UNSPECIFIED VENOUS COMPLICATION, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
671.92	ICD-9-CM	Inpatient	UNSPECIFIED VENOUS COMPLICATION, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
672.02	ICD-9-CM	Inpatient	PYREXIA OF UNKNOWN ORIGIN, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
673.01	ICD-9-CM	Inpatient	OBSTETRICAL AIR EMBOLISM, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
673.02	ICD-9-CM	Inpatient	OBSTETRICAL AIR EMBOLISM, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes and Current Procedural Terminology, 4th Edition (CPT-4) Procedure Codes Used to Define Live Birth Deliveries in this Request

Code	Code Type	Care Setting	Description
673.11	ICD-9-CM	Inpatient	AMNIOTIC FLUID EMBOLISM, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
673.12	ICD-9-CM	Inpatient	AMNIOTIC FLUID EMBOLISM, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
673.21	ICD-9-CM	Inpatient	OBSTETRICAL BLOOD-CLOT EMBOLISM, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARUM COND
673.22	ICD-9-CM	Inpatient	Obstetrical blood-clot embolism, delivered, with mention of postpartum complication
673.31	ICD-9-CM	Inpatient	OBSTETRICAL PYEMIC AND SEPTIC EMBOLISM, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
673.32	ICD-9-CM	Inpatient	OBSTETRICAL PYEMIC AND SEPTIC EMBOLISM, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
673.81	ICD-9-CM	Inpatient	OTHER OBSTETRICAL PULMONARY EMBOLISM, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
673.82	ICD-9-CM	Inpatient	OTHER OBSTETRICAL PULMONARY EMBOLISM, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
674.01	ICD-9-CM	Inpatient	CEREBROVASCULAR DISORDERS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
674.02	ICD-9-CM	Inpatient	CEREBROVASCULAR DISORDERS, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
674.12	ICD-9-CM	Inpatient	DISRUPTION OF CESAREAN WOUND, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
674.22	ICD-9-CM	Inpatient	DISRUPTION OF PERINEAL WOUND, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
674.32	ICD-9-CM	Inpatient	OTHER COMPLIC OF OBSTET SURG WOUNDS, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
674.42	ICD-9-CM	Inpatient	PLACENTAL POLYP, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
674.51	ICD-9-CM	Inpatient	Peripartum cardiomyopathy, delivered, with or without mention of antepartum condition
674.52	ICD-9-CM	Inpatient	Peripartum cardiomyopathy, delivered, with mention of postpartum condition
674.82	ICD-9-CM	Inpatient	OTHER COMPLICATIONS OF PUERPERIUM, WITH DELIVERY, WITH MENT POSTPARTUM COMP
674.92	ICD-9-CM	Inpatient	UNSPECIFIED COMPLICATIONS OF PUERPERIUM, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
675.01	ICD-9-CM	Inpatient	INFECTION OF NIPPLE, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
675.02	ICD-9-CM	Inpatient	INFECTION OF NIPPLE, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
675.11	ICD-9-CM	Inpatient	ABSCESS OF BREAST, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
675.12	ICD-9-CM	Inpatient	ABSCESS OF BREAST, WITH DELIVERY, WITH MENTION POSTPARTUM COND
675.21	ICD-9-CM	Inpatient	NONPURULENT MASTITIS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
675.22	ICD-9-CM	Inpatient	NONPURULENT MASTITIS, WITH DELIVERY, WITH MENTION POSTPARTUM COND
675.81	ICD-9-CM	Inpatient	OTHER SPEC INFECT OF BREAST, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND

Code	Code Type	Care Setting	Description
675.82	ICD-9-CM	Inpatient	OTHER SPEC INFECT OF BREAST, WITH DELIVERY, WITH MENTION POSTPARTUM COND
675.91	ICD-9-CM	Inpatient	UNSPEC INFECT OF BREAST, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
675.92	ICD-9-CM	Inpatient	UNSPEC INFECT OF BREAST, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
676.01	ICD-9-CM	Inpatient	RETRACTED NIPPLE, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
676.02	ICD-9-CM	Inpatient	RETRACTED NIPPLE, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
676.11	ICD-9-CM	Inpatient	CRACKED NIPPLE, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
676.12	ICD-9-CM	Inpatient	CRACKED NIPPLE, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
676.21	ICD-9-CM	Inpatient	ENGORGEMENT OF BREASTS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
676.22	ICD-9-CM	Inpatient	ENGORGEMENT OF BREASTS, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
676.31	ICD-9-CM	Inpatient	OTHER DISORDER OF BREASTS, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
676.32	ICD-9-CM	Inpatient	OTHER DISORDER OF BREASTS, WITH DELIVERY, WITH MENTION POSTPARTUM COMP
676.41	ICD-9-CM	Inpatient	FAILURE OF LACTATION, WITH DELIVERY, WITH OR WITHOUT MENT ANTEPARTUM COND
676.42	ICD-9-CM	Inpatient	FAILURE OF LACTATION, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
676.51	ICD-9-CM	Inpatient	SUPPRESSED LACTATION, WITH DELIVERY, WITH OR WITHOUT MENTION ANTEPARTUM COND
676.52	ICD-9-CM	Inpatient	SUPPRESSED LACTATION, WITH DELIVERY, WITH MENTION OF POSTPARTUM COMP
676.61	ICD-9-CM	Inpatient	GALACTORRHEA, WITH DELIVERY, WITH OR WITHOUT MENTION OF ANTEPARTUM COND
676.62	ICD-9-CM	Inpatient	GALACTORRHEA, WITH DELIVERY, WITH MENTION OF POSTPARTUM C
676.81	ICD-9-CM	Inpatient	OTHER DISORDERS OF LACTATION, WITH DELIVERY, WITH OR WITH
676.82	ICD-9-CM	Inpatient	OTHER DISORDERS OF LACTATION, WITH DELIVERY, WITH MENTION
676.91	ICD-9-CM	Inpatient	UNSPECIFIED DISORDER OF LACTATION, WITH DELIVERY, WITH OR
676.92	ICD-9-CM	Inpatient	UNSPECIFIED DISORDER OF LACTATION, WITH DELIVERY, WITH ME
678.01	ICD-9-CM	Inpatient	Fetal hematologic conditions, delivered, with or without mention of antepartum condition
678.11	ICD-9-CM	Inpatient	Fetal conjoined twins, delivered, with or without mention of antepartum condition
679.01	ICD-9-CM	Inpatient	Maternal complications from in utero procedure, delivered with or without mention of antepartum condition
679.02	ICD-9-CM	Inpatient	Maternal complications from in utero procedure, delivered with mention of postpartum condition
679.11	ICD-9-CM	Inpatient	Fetal complications from in utero procedure, delivered, with or without mention of antepartum condition
679.12	ICD-9-CM	Inpatient	Fetal complications from in utero procedure, delivered with mention of postpartum condition
763.0	ICD-9-CM	Inpatient	BREECH DELIVERY AND EXTRACTION AFFECTING FETUS OR NEWBORN
763.2	ICD-9-CM	Inpatient	FORCEPS DELIVERY AFFECTING FETUS OR NEWBORN
763.3	ICD-9-CM	Inpatient	DELIVERY BY VACUUM EXTRACTOR AFFECTING FETUS OR NEWBORN
763.4	ICD-9-CM	Inpatient	CESAREAN DELIVERY AFFECTING FETUS OR NEWBORN
763.6	ICD-9-CM	Inpatient	PRECIPITATE DELIVERY AFFECTING FETUS OR NEWBORN
768.0	ICD-9-CM	Inpatient	Fetal death from asphyxia or anoxia before onset of labor or at unspecified time

Code	Code Type	Care Setting	Description
768.1	ICD-9-CM	Inpatient	Fetal death from asphyxia or anoxia during labor
V27	ICD-9-CM	Inpatient	OUTCOME OF DELIVERY
V27.0	ICD-9-CM	Inpatient	SINGLE NEWBORN
V27.1	ICD-9-CM	Inpatient	SINGLE STILLBORN
V27.2	ICD-9-CM	Inpatient	TWINS, BOTH LIVEBORN
V27.3	ICD-9-CM	Inpatient	TWINS, ONE LIVEBORN
V27.4	ICD-9-CM	Inpatient	TWINS, STILLBORN
V27.5	ICD-9-CM	Inpatient	OTHER MULTIPLE BIRTH, ALL LIVEBORN
V27.6	ICD-9-CM	Inpatient	OTHER MULTIPLE BIRTH, SOME LIVEBORN
V27.7	ICD-9-CM	Inpatient	OTHER MULTIPLE BIRTH, ALL STILLBORN
V27.9	ICD-9-CM	Inpatient	MOTHER WITH UNSPECIFIED OUTCOME OF DELIVERY
V30	ICD-9-CM	Inpatient	SINGLE LIVEBORN
V30.0	ICD-9-CM	Inpatient	SINGLE NEWBORN, BORN IN HOSPITAL
V30.00	ICD-9-CM	Inpatient	SINGLE NEWBORN, BORN IN HOSPITAL, DELIVERED WITHOUT MENTION OF CESAREAN
V30.01	ICD-9-CM	Inpatient	SINGLE NEWBORN, BORN IN HOSPITAL, CESAREAN
V30.1	ICD-9-CM	Inpatient	Single liveborn, born before admission to hospital
V30.2	ICD-9-CM	Inpatient	Single liveborn, born outside hospital and not hospitalized
V31	ICD-9-CM	Inpatient	TWIN BIRTH, MATE LIVEBORN
V31.0	ICD-9-CM	Inpatient	TWIN BIRTH MATE LIVEBORN, BORN IN HOSPITAL
V31.00	ICD-9-CM	Inpatient	TWIN BIRTH MATE LIVEBORN, BORN IN HOSPITAL DELIEVERED WITHOUT MENTION OF CESAREAN
V31.01	ICD-9-CM	Inpatient	TWIN BIRTH MATE LIVEBORN, BORN IN HOSPITAL DELIVERED BY CESAREAN SECTION
V31.1	ICD-9-CM	Inpatient	Twin birth, mate liveborn, born before admission to hospital
V31.2	ICD-9-CM	Inpatient	Twin birth, mate liveborn, born outside hospital and not hospitalized
V32	ICD-9-CM	Inpatient	Twin birth mate stillborn
V32.0	ICD-9-CM	Inpatient	TWIN, BORN IN HOSPITAL, MATE STILLBORN
V32.00	ICD-9-CM	Inpatient	Twin birth mate stillborn born in hospital, delivered without mention of cesarean section
V32.01	ICD-9-CM	Inpatient	TWIN, BORN IN HOSPITAL, CESAREAN, MATE STILLBORN
V32.1	ICD-9-CM	Inpatient	Twin birth, mate stillborn, born before admission to hospital
V32.2	ICD-9-CM	Inpatient	Twin birth, mate stillborn, born outside hospital and not hospitalized
V33	ICD-9-CM	Inpatient	Twin birth unspecified whether mate liveborn or stillborn
V33.0	ICD-9-CM	Inpatient	Twin birth unspecified whether mate liveborn or stillborn born in hospital
V33.00	ICD-9-CM	Inpatient	Twin birth, unspecified whether mate liveborn or stillborn, born in hospital, delivered without mention of cesarean section
V33.01	ICD-9-CM	Inpatient	TWIN, BORN IN HOSPITAL, CESAREAN
V33.1	ICD-9-CM	Inpatient	Twin birth, unspecified whether mate liveborn or stillborn, born before admission to hospital
V33.2	ICD-9-CM	Inpatient	Twin birth, unspecified whether mate liveborn or stillborn, before outside hospital and not hospitalized
V34	ICD-9-CM	Inpatient	Other multiple birth (three or more) mates all liveborn
V34.0	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes and Current Procedural Terminology, 4th Edition (CPT-4) Procedure Codes Used to Define Live Birth Deliveries in this Request

Code	Code Type	Care Setting	Description
V34.00	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL
V34.01	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL, CESAREAN
V34.1	ICD-9-CM	Inpatient	Other multiple birth (three or more), mates all liveborn, born before admission to hospital
V34.2	ICD-9-CM	Inpatient	Other multiple birth (three or more), mates all liveborn, born outside hospital and not hospitalized
V35	ICD-9-CM	Inpatient	OTHER MULTIPLE, mates stillborn
V35.0	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL, mates stillborn
V35.00	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL, mates stillborn
V35.01	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL, CESAREAN, mates stillborn
V35.1	ICD-9-CM	Inpatient	Other multiple birth (three or more), mates all stillborn, born before admission to hospital
V35.2	ICD-9-CM	Inpatient	Other multiple birth (three or more), mates all stillborn, born outside hospital and not hospitalized
V36	ICD-9-CM	Inpatient	Other multiple birth (three or more), mates liveborn and stillborn
V36.0	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL, mates liveborn and stillborn
V36.00	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL, mates liveborn and stillborn
V36.01	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL, CESAREAN, mates liveborn and stillborn
V36.1	ICD-9-CM	Inpatient	Other multiple birth (three or more), mates liveborn and stillborn, born before admission to hospital
V36.2	ICD-9-CM	Inpatient	Other multiple birth (three or more), mates liveborn and stillborn, born outside hospital and not hospitalized
V37	ICD-9-CM	Inpatient	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn
V37.0	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL
V37.00	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL
V37.01	ICD-9-CM	Inpatient	OTHER MULTIPLE, BORN IN HOSPITAL, CESAREAN
V37.1	ICD-9-CM	Inpatient	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn, born before admission to hospital
V37.2	ICD-9-CM	Inpatient	Other multiple birth (three or more), unspecified whether mates liveborn or stillborn, born outside hospital and not hospitalized
V39	ICD-9-CM	Inpatient	Liveborn, unspecified whether single, twin or multiple
V39.0	ICD-9-CM	Inpatient	Liveborn, unspecified whether single, twin or multiple, born in hospital
V39.00	ICD-9-CM	Inpatient	Liveborn, unspecified whether single, twin or multiple, born in hospital without mention of Cesarean
V39.01	ICD-9-CM	Inpatient	Liveborn, unspecified whether single, twin or multiple, born in hospital delivered by Cesarean section
V39.1	ICD-9-CM	Inpatient	Liveborn, unspecified whether single, twin or multiple, born before admission to hospital
V39.2	ICD-9-CM	Inpatient	Liveborn, unspecified whether single, twin or multiple, born outside hospital and not hospitalized

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnosis Codes Used to Define the Sub-Cohort Inclusion Criteria in this Request

Code	Description	Code Type
Diabetes		
250.0	Diabetes mellitus without mention of complication	ICD-9-CM
250.1	Diabetes with ketoacidosis	ICD-9-CM
250.2	Diabetes with hyperosmolarity	ICD-9-CM
250.3	Diabetes with other coma	ICD-9-CM
250.4	Diabetes with renal manifestations	ICD-9-CM
250.5	Diabetes with ophthalmic manifestations	ICD-9-CM
250.6	Diabetes with neurological manifestations	ICD-9-CM
250.7	Diabetes with peripheral circulatory disorders	ICD-9-CM
250.8	Diabetes with other specified manifestations	ICD-9-CM
250.9	Diabetes with unspecified complication	ICD-9-CM
Lupus		
710	Systemic lupus erythematosus	ICD-9-CM
Multiple Sclerosis		
340	Multiple sclerosis	ICD-9-CM
Gestational Diabetes		
648.80	Abnormal maternal glucose tolerance, complicating pregnancy, childbirth, or the puerperium, u	ICD-9-CM
648.81	Abnormal maternal glucose tolerance, with delivery	ICD-9-CM
648.82	Abnormal maternal glucose tolerance, with delivery, with current postpartum complication	ICD-9-CM
648.83	Abnormal maternal glucose tolerance, antepartum	ICD-9-CM
648.84	Abnormal maternal glucose tolerance complicating pregnancy, childbirth, or the puerperium, pc	ICD-9-CM

Appendix F. List of Gestational Diabetes Definitions Used for Sub-Cohort Inclusion Criteria in this Request

Gestational Diabetes Definition 1
▪Exclude women with ICD-9-CM code 250.X during the 183 days prior to the pregnancy episode.
▪Exclude women with ICD-9-CM code 250.X during the first trimester of the pregnancy episode.
▪Include women with a gestational diabetes code 648.8X during the second or third trimester.

Gestational Diabetes Definition 2
▪Include women with ICD-9-CM code 648.8X in the second or third trimester.
▪Exclude women with ICD-9-CM code 648.8X in the first trimester (but not in the second or third trimester).

Gestational Diabetes Definition 3
▪Include women with ICD-9-CM code 648.8X at any time during the pregnancy episode.

Women without Gestational Diabetes
▪Women without ICD-9-CM code 648.8X at any time during the pregnancy episode.